EP2405940B1 - Antibodies to clostridium difficile toxins - Google Patents
Antibodies to clostridium difficile toxins Download PDFInfo
- Publication number
- EP2405940B1 EP2405940B1 EP10706731.6A EP10706731A EP2405940B1 EP 2405940 B1 EP2405940 B1 EP 2405940B1 EP 10706731 A EP10706731 A EP 10706731A EP 2405940 B1 EP2405940 B1 EP 2405940B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- toxin
- difficile
- antibody
- antibodies
- toxinotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims description 172
- 231100000765 toxin Toxicity 0.000 title claims description 154
- 239000003053 toxin Substances 0.000 title claims description 152
- 108700012359 toxins Proteins 0.000 title description 154
- 101710182223 Toxin B Proteins 0.000 claims description 94
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims description 76
- 101710182532 Toxin a Proteins 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 50
- 238000002649 immunization Methods 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 230000002163 immunogen Effects 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 230000004071 biological effect Effects 0.000 claims description 9
- 230000000890 antigenic effect Effects 0.000 claims description 8
- 230000009260 cross reactivity Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 62
- 208000037384 Clostridium Infections Diseases 0.000 description 60
- 206010054236 Clostridium difficile infection Diseases 0.000 description 60
- 239000012634 fragment Substances 0.000 description 52
- 241000283898 Ovis Species 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 23
- 230000027455 binding Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 19
- 239000002671 adjuvant Substances 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 239000000872 buffer Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 230000003472 neutralizing effect Effects 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 241000699673 Mesocricetus auratus Species 0.000 description 10
- 229960002227 clindamycin Drugs 0.000 description 10
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000001332 colony forming effect Effects 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 239000002619 cytotoxin Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000001147 anti-toxic effect Effects 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 4
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 108700022831 Clostridium difficile toxB Proteins 0.000 description 3
- 101710112752 Cytotoxin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021333 Ileus paralytic Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 241001416149 Ovis ammon Species 0.000 description 2
- 241000283903 Ovis aries Species 0.000 description 2
- 241001502414 Ovis canadensis Species 0.000 description 2
- 241000283902 Ovis dalli Species 0.000 description 2
- 241000565625 Ovis nivicola Species 0.000 description 2
- 241001209538 Ovis orientalis Species 0.000 description 2
- 241000611732 Ovis vignei Species 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 244000144992 flock Species 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000004840 megacolon Diseases 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 201000007620 paralytic ileus Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 231100000654 protein toxin Toxicity 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000097 Abdominal tenderness Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 241001522791 Clostridioides difficile R20291 Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108010021408 Clostridium perfringens iota toxin Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108091023242 Internal transcribed spacer Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- RGUZLDGEKZUCSS-POYBYMJQSA-N [(2r)-2-[(1r)-1-(2,4-dioxopyrimidin-1-yl)-2-oxoethoxy]-3-oxopropyl] phosphono hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OC[C@H](C=O)O[C@H](C=O)N1C=CC(=O)NC1=O RGUZLDGEKZUCSS-POYBYMJQSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126572 wide-spectrum antibiotic Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
Definitions
- the present invention relates to ovine antibodies and their use in the prevention or treatment of Clostridium difficile infection (CDI).
- CDI Clostridium difficile infection
- Clostridium difficile infection is now a major problem in hospitals worldwide.
- the bacterium causes nosocomial, antibiotic-associated disease which manifests itself in several forms ranging from mild self-limiting diarrhoea to potentially life-threatening, severe colitis.
- Elderly patients are most at risk from these potentially life-threatening diseases and incidents of CDI have increased dramatically over the last 10 years.
- CDI costs the NHS >£500M per annum.
- the various strains of C. difficile may be classified by a number of methods.
- One of the most commonly used is polymerase chain reaction (PCR) ribotyping in which PCR is used to amplify the 16S-23S rRNA gene intergenic spacer region of C. difficile. Reaction products from this provide characteristic band patterns identifying the bacterial ribotype of isolates.
- Toxinotyping is another typing method in which the restriction patterns derived from DNA coding for the C. difficile toxins are used to identify strain toxinotype. The differences in restriction patterns observed between toxin genes of difference strains are also indicative of sequence variation within the C. difficile toxin family. Toxin B shows sequence variation in some regions.
- Strains of C. difficile produce a variety of virulence factors, notable among which are several protein toxins: Toxin A, Toxin B and, in some strains, a binary toxin which is similar to Clostridium perfringens iota toxin.
- Toxin A is a large protein cytotoxin/enterotoxin which plays a role in the pathology of infection and may influence in the gut colonisation process.
- Outbreaks of CDI have been reported with Toxin A-negative/Toxin B-positive strains which suggests that Toxin B is also capable of playing a key role in the disease pathology.
- Both Toxins A and B exert their mechanisms of action via multi-step mechanisms which include binding to receptors on the cell surface, internalisation followed by translocation and release of the effector domain into the cell cytosol and finally intracellular action.
- each toxin catalyses the transfer of a glucose moiety (from UDP-glucose) onto an amino residue of the Rho protein.
- Both Toxins A and B also contain a second enzyme activity in the form of a cysteine protease which appears to play a role in the release of the effector domain into the cytosol after translocation.
- the C. difficile binary toxin works in a different way, modifying cell actin by a mechanism which involves the transfer of an ADP-ribose moiety from NAD onto its target protein.
- C. difficile infection currently relies on antibiotics of which metronidazole and vancomycin constitute the treatment of choice.
- these antibiotics are not effective in all cases and 20-30% of patients suffer relapse of the disease.
- Of major concern is the appearance in the UK of more virulent strains which were first identified in Canada in 2002. These strains, which belong to PCR ribotype 027, toxinotype III, cause CDI with a directly attributable mortality more than 3-fold that observed previously.
- the present invention provides ovine polyclonal antibodies, for use as defined according to the claims.
- the antibodies of the invention bind a C. difficile toxin or a fragment thereof and neutralise the biological activity of the toxin or fragment thereof. Accordingly, the antibodies of the present invention are capable of preventing or treating CDI, and preferably also preventing a relapse in a patient.
- the antibodies of the present invention provide a distinct advantage over other therapeutics in that they are able to inhibit the biological action of one or more of the toxins of C. difficile, whilst having a low immunogenic effect on a patient. Moreover, the antibodies of the present invention can be produced in high titres. Thus, the ovine antibodies can be readily obtained and can protect and/ or the patient against the pathological effects produced by C. difficile with minimal side-effects. The antibodies of the present invention may also be utilised in the development of a vaccine for passive immunization against CDI.
- the antibody composition of the present invention comprises ovine antibodies that bind to and neutralise C. difficile Toxin A (or a fragment thereof) and to C. difficile Toxin B (or a fragment thereof).
- the antibody composition of the present invention may also comprise ovine antibodies that bind to and/or neutralise C. difficile Binary Toxin (or a fragment thereof).
- the antibody composition comprises a first antibody that binds to and neutralises C. difficile Toxin A (or a fragment thereof), and a second antibody antibody that binds to and neutralises C. difficile Toxin B (or a fragment thereof), and optionally includes a third antibody that binds to and/ or neutralises C. difficile Binary Toxin (or a fragment thereof).
- the antibody composition comprises a first antibody that binds to and neutralises C. difficile Toxin B (or a fragment thereof), and a second antibody that binds to and neutralises C. difficile Toxin A (or a fragment thereof), and optionally includes a third antibody that binds to and/ or neutralises C. difficile Binary Toxin (or a fragment thereof).
- An antibody of the invention may specifically bind and neutralise one of C. difficile Toxin A (or a fragment thereof) or C. difficile Toxin B (or a fragment thereof).
- the antibodies of the present invention interact with specific epitopes of the toxin.
- an antibody can bind an epitope in the N-terminal domain (e.g. between amino acids 1-957) or the mid-region domains (e.g. between amino acids 958-1831) or the C-terminal repeat domains (e.g. between amino acids 1832-2710) of C. difficile Toxin A.
- the antibody may bind to an epitope within amino acids 1832-2710 of C. difficile Toxin A.
- an antibody can bind an epitope in the N-terminal domain (e.g. between amino acids 1-955) or the mid-region domains (e.g.
- an antibody may bind to an epitope within amino acids 1832-2366 of Toxin B.
- the binary toxin antibodies may bind to the catalytic domain (Fragment A) or the receptor binding domain, which resides in the C-terminal portion of Fragment B (approx residues 400-870); and/ or to the N-terminal half of Fragment B (approx residues 1-400), which is involved in the binding and translocation of Fragment A into the cell.
- the C. difficile toxin is selected from one of toxinotypes 0 to XV.
- Preferred toxinotypes are listed in Table 1 immediately below. The listed toxinotypes are purely illustrative and are not intended to be limiting to the present invention.
- Table 1 Toxinotype Example Ribotypes Example Strains Reference 0 001, 106 VPI10463 I 003, 012, 102 EX623 II 103 AC008 Rupnik et al. (1998) III 027, 034, 075, 080 R20291, QCD-32g58 IV 023, 034, 075, 080 55767 J. Clinical Microbiol.
- Different antibodies of the present invention may bind to and neutralise the same or different strains of C. difficile toxin.
- the antibodies may bind to and neutralise one or more of the following: C. difficile Toxin A - Toxinotype 0; C. difficile Toxin B - Toxinotype 0; C. difficile Toxin A - Toxinotype III; C. difficile Toxin B - Toxinotype III; C. difficile Toxin A - Toxinotype V; and/or C. difficile Toxin B - Toxinotype V.
- a mixture of antibodies is employed, which bind to and neutralise Toxins A and B from all of these Toxinotypes.
- An antibody of the present invention may bind to an epitope in the N-terminal domain, the mid-region domain, and/or the C-terminal repeat domain of said strains of C. difficile Toxin A and/or C. difficile Toxin B.
- the antibodies of the present invention may bind to and neutralise at least one C. difficile toxin comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99%, or more identical to SEQ ID NOs: 1-6, or a fragment thereof.
- the patient can be infected with C. difficile, or have a symptom of C. difficile (e.g. mild self-limiting diarrhoea, abdomen pain, fever and loss of appetite to life-threatening conditions such as pseudomembranous colitis and cytotoxic megacolon) or have a predisposition towards C. difficile infection (e.g. undergoing treatment with antibiotics, having experienced C. difficile and at risk of relapse, or exposed to a second individual who has shown the clinical symptoms associated with C. difficile infection).
- the present invention thereby provides an effective means for preventing or treating CDI.
- the antibody composition for use according to the present invention may be administered to a patient infected with C. difficile, or suffering from the symptoms of CDI. This can be accomplished using a therapeutically effective amount of the antibodies. Such administration may be effected by repeated administrations of antibody compositions of the present invention, for a prolonged period of time.
- the antibody components of said compositions may be the same or different (in terms of their toxinotype specificity and/ or targeted binding region or epitope on a C. difficile Toxin), and administration can be concurrent or sequential, and can be effected in any order.
- the antibodies for use according to the invention provide passive immunity against CDI. This can be accomplished using a prophylactically effective amount of the antibodies prior to the onset or in the very early stages of CDI. Such administration may be effected by repeated administrations of antibody compositions of the present invention, for a prolonged period of time.
- the antibody components of said compositions may be the same or different (in terms of their toxinotype specificity and/ or targeted binding region or epitope on a C. difficile Toxin), and administration can be concurrent or sequential, and can be effected in any order.
- the ovine antibodies are antibodies which have been raised in a sheep.
- the present invention includes a method of producing ovine polyclonal antibodies for use according to the invention, said method generally involving (i) administering an immunogen comprising a C. difficile toxin or a fragment thereof to a sheep, (ii) allowing sufficient time for the generation of antibodies in the sheep, and (iii) obtaining the antibodies from the sheep.
- sheep comprise any species that fall within the Ovis genus (e.g. Ovis ammon, Ovis orientalis aries, Ovis orientalis orientalis, Ovis orientalis vignei, Ovis Canadensis, Ovis dalli, Ovis nivicola).
- the present invention also includes a method of producing ovine antibodies for use in the antibody composition of the invention, wherein the ovine antibodies are elicited by a sheep in response to an immunogen comprising a C. difficile toxin or a fragment thereof (preferably a fragment that possesses antigenic cross-reactivity with the full-length natural Toxin and/ or retains the toxin or toxin-like activity of the full-length natural Toxin).
- an immunogen comprising a C. difficile toxin or a fragment thereof (preferably a fragment that possesses antigenic cross-reactivity with the full-length natural Toxin and/ or retains the toxin or toxin-like activity of the full-length natural Toxin).
- the antibody may be obtained from the sheep serum.
- the procedures generate sheep antisera containing antibodies capable of binding and neutralising C. difficile toxins.
- the antibodies are isolated and/or purified.
- another aspect of the present invention involves purifying the antibodies from sheep antiserum.
- the immunogen used to generate the antibodies of the present invention is a C. difficile toxin or a fragment thereof, which has optionally been purified.
- Suitable C. difficile toxins include any C. difficile toxins that cause or are associated with CDI or a symptom thereof.
- the toxin is selected from at least one of the following toxins: C. difficile Toxin A or a fragment thereof, C. difficile Toxin B or a fragment thereof and C. difficile Binary Toxin or a fragment thereof.
- the C. difficile toxin may also be a toxin selected from one of the toxinotypes 0 to XV as defined hereinbefore.
- the immunogen is a C. difficile toxin variant.
- the immunogen comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99%, or more identical to SEQ ID NOs: 1-6, or a fragment thereof.
- the immunogen used to generate the antibodies of the present invention may also be partially or completely inactivated, i.e. have reduced toxicity.
- modification include: chemical treatment (e.g. treatment with UDP-dialdehyde, formaldehyde, glutaraldehyde, peroxide, or oxygen) and recombinant methods (e.g. deletions or mutations in the toxin).
- the immunogen may be a C. difficile toxoid or a fragment thereof derived from the native toxin by treatment with formaldehyde.
- a recombinant toxoid may be generated by selectively inactivating the active site motif by site-directed mutagenesis.
- An example of site directed mutagenesis to reduce or ablate the toxin effects of Toxins A and B is modification of the DXD motif in the N-terminal domain of the toxin.
- the aspartates and/or other residues may be mutated to e.g. alanine in order to reduce the biological activity of either Toxin A and B.
- Toxin A one of more of the following amino acids may be mutated: Asp 269, Asp285, Asp 287, Asn383, Trp519, Tyr283, Arg272.
- Toxin B one of more of the following amino acids may be mutated: Asp270, Asp286, Asp 288, Asn384, Trp520, Tyr284, Arg273.
- Antigens may be formulated with an adjuvant.
- Suitable adjuvants may include alum (aluminium phosphate or aluminium hydroxide), which is used widely in humans, and other adjuvants such as saponin and its purified component Quil A, Freund's complete adjuvant, RIBBI adjuvant, and other adjuvants used in research and veterinary applications.
- the C. difficile toxins or toxoids may be used as immunogens separately or in combination, either concurrently or sequentially, in order to produce antibodies specific for individual C. difficile toxins or combinations.
- two or more toxins or toxoids may be mixed together and used as a single immunogen.
- a C. difficile toxin e.g. C. difficile Toxin A
- another C. difficile toxin e.g. C. difficile Toxin B
- the antibodies produced by separate immunisation may be combined to yield an antibody composition directed against C. difficile toxins.
- the method comprises all modes of immunisation, including subcutaneous, intramuscular, intraperitoneal, and intravenous.
- the invention also contemplates a wide variety of immunisation schedules.
- a sheep or goat is administered toxin(s) on day zero and subsequently receives toxin(s) at intervals thereafter.
- the interval range and dosage range required depends on the precise nature of the immunogen, the route of administration, the nature of the formulation, and the judgement of the attending person. Variations in these dosage levels can be adjusted using standard empirical routines for optimisation.
- the preferred collection time is someday after day 56.
- Levels of the specific antibody, i.e. that which binds to the immunogen should represent at least 3 g per litre of serum.
- the antibodies of the invention may be modified as necessary after collection, so that, in certain instances, they are less immunogenic in the patient to whom they are administered.
- the antibodies may be despeciated by methods well known in the art.
- One example as to how an antibody can be made less immunogenic is to prepare the (Fab) 2 fragment.
- the antibodies of the invention may be used to produce such antibody fragments for which various techniques have been developed. For example, the fragments may be derived by proteolytic digestion of intact antibodies. Other techniques for their production will be apparent to the skilled practitioner.
- the present invention employs a pharmaceutical composition, comprising the antibody composition of the present invention in a form suitable for parenteral, usually intravenous administration.
- the purified intact antibodies, or their fragments are formulated for such delivery.
- antibody, or its fragment at a concentration between 5-50 or 15-50 or 25-50 g/litre may be formulated in buffer.
- suitable buffer components include physiological salts such as sodium citrate and/ or citric acid.
- Preferred buffers contain 100-200 or 125-175 or approximately 150 (eg. 153) mM physiological salts such as sodium chloride.
- Preferred buffers maintain the pharmaceutical composition at a pH that is close to the physiological pH of the patient - for example, at a pH of 5.5-6.4, or at a pH of 5.6-6.3, or at a pH of 5.7-6.2, or at a pH of 5.8-6.2.
- the antibody-containing compositions of the present invention preferably exclude adjuvant(s) as it is undesirable to stimulate an immune response against said antibodies in the patient.
- Antibodies of the invention may be formulated for, but not limited to intramuscular, subcutaneous or intravenous delivery.
- Compositions suitable for intramuscular, subcutaneous or intravenous injection include sterile aqueous solutions. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- the antibody compositions of the present invention are not oral formulations, and this mode of administration is not employed. In this regard, a key problem with oral delivery is ensuring that sufficient antibody reaches the colon where it is required.
- Factors which prevent antibody reaching the gut include the proteolytic enzymes present in the digestive secretions, which degrade the antibody molecule and also in some instances the effect of CDI itself which can cause paralytic ileus and other complications that prevent movement of fluids down the alimentary canal.
- compositions suitable for injection may be in the form of solutions, suspensions or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
- preparing solutions of the antibodies or their fragments can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing.
- Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal or suspending and/or local anaesthetic agents may be dissolved in the vehicle.
- Dry powders which are dissolved or suspended in a suitable vehicle prior to use, may be prepared by filling pre-sterilised ingredients into a sterile container using aseptic technique in a sterile area. Alternatively the ingredients may be dissolved into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
- the dosage ranges for administration of the antibodies of the present invention are those to produce the desired therapeutic effect. It will be appreciated that the dosage range required depends on the precise nature of the antibody or composition, the route of administration, the nature of the formulation, the age of the patient, the nature, extent or severity of the patient's condition, contraindications, if any, and the judgement of the attending physician. Variations in these dosage levels can be adjusted using standard empirical routines for optimisation.
- Suitable daily dosages are in the range of 5-20mg per kg of body weight.
- the unit dosage can vary from less than 100mg, but typically will be in the region of 250-2000 mg per dose, which may be administered daily or less frequently (e.g. on alternative days for up to 1 week)
- the antibodies of the invention may be administered in conjunction with a suitable antibiotic (e.g. metronidazole and/or vancomycin)
- combination treatment may be carried out in any way as deemed necessary or convenient by the person skilled in the art and for the purpose of this specification, no limitations with regard to the order, amount, repetition or relative amount of the compounds to be used in combination is contemplated.
- Clostridium difficile is a species of Gram-positive bacteria of the genus Clostridium.
- Clostridium difficile infection means a bacterial infection which affects humans and animals and which results in a range of symptoms from mild self-limiting diarrhoea to life-threatening conditions such as pseudomembranous colitis and cytotoxic megacolon. In this disease, C. difficile replaces the normal gut flora and produces cytotoxins which attack and damage the gut epithelium.
- Primary risk factors for human CDI include: receiving broad-spectrum antibiotics, over 65 years old and hospitalised.
- Clostridium difficile Toxin A is a family of protein cytotoxins/enterotoxins of approximately 300 kDa in size. Toxin A has an enzyme activity within the N-terminal region which acts to disrupt the cytoskeleton of the mammalian cell causing cell death. There are a number of naturally occurring variants of Toxin A within the strains of Clostridium difficile which are call 'toxinotypes'. The various toxinotypes of Toxin A have variations within their primary sequence of usually ⁇ 10% overall. Examples of suitable Toxin A sequences include SEQ ID Nos: 1 and 3.
- Clostridium difficile Toxin B is a family of protein cytotoxins of approximately 270 kDa in size which are similar to Toxin A but significantly more cytotoxic. Like Toxin A, Toxin B has an enzyme activity within the N-terminal region which acts to disrupt the cytoskeleton of the mammalian cell causing cell death. There are a number of naturally occurring variants of Toxin B within the strains of C. difficile which are call 'toxinotypes'. The various toxinotypes of Toxin B have variations within their primary sequence of usually ⁇ 15% overall. Examples of suitable Toxin A sequences include SEQ ID Nos: 2 and 4.
- Binary Toxin is a two component cytotoxin produced by some but not all strains of C. difficile.
- the binary toxins are similar in action to Clostridium botulinum C2 and Clostridium perfringens iota toxins, which like C. difficile binary toxin, consist of a cell binding fragment of approximately 100 kDa and an enzymically active 'effector' fragment of approx. 50 kDa.
- suitable Binary Toxin sequences include SEQ ID Nos: 5 and 6.
- the term "toxin” encompasses said toxin fragments.
- the fragment may range from any number of amino acids between 10 and 2700 (e.g. at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 750, 1000, 1500, 2000 or 2500) of the reference toxin.
- the fragment preferably includes at least one epitope of the gene product in question.
- the "fragment” may also have a common antigenic cross-reactivity and/or substantially the same in vivo biological activity as the toxin from which it is derived. For example, an antibody capable of binding to a fragment would be also capable of binding to the toxin from which it is derived.
- the fragment may share a common ability to induce a "recall response" of a T-lymphocyte which has been previously exposed to an antigenic component of a C. difficile toxin.
- Toxin embraces "variants" thereof - for example, a peptide or peptide fragment having at least 80 or 85 or 90 or 95 or 96 or 97 or 98 or 99 percent amino acid sequence homology with a C. difficile Toxin.
- a "variant” may be a mimic of the peptide or peptide fragment, which mimic reproduces at least one epitope of the peptide or peptide fragment.
- Toxin Reference to the Toxin embraces Toxin “toxoid”, which is discussed in more detail below.
- Toxinotypes are often used to classify strains of C. difficile. Toxinotypes are based on a method which characterises the restriction patterns obtained with the toxin genes. As described above, toxinotypes of Toxins A and B represent variants, by primary amino acid sequence, of these protein toxins.
- Clostridium difficile Toxoid is used to describe a C. difficile toxin (Toxin A, Toxin B or Binary Toxin) or a mixture of C. difficile toxins that has been partially or completely inactivated.
- a toxin is considered inactivated if it has less toxicity (e.g. 100%, 99%, 95% or 90% less toxicity) than untreated toxin as measured by an in vitro cytotoxicity assay or by animal toxicity.
- An antibody that binds to a toxin of interest is one capable of binding that toxin with sufficient affinity such that the antibody is useful as a therapeutic agent.
- An antibody that binds to a toxin of interest is one that binds to a toxin of C. difficile with an affinity (K a ) of at least 10 4 M.
- Toxin neutralising means the action of a substance (e.g. an antibody) which blocks the biological action of one or more of the cytotoxins (Toxin A and/or Toxin B and/or binary toxin) of C. difficile.
- the cytotoxin's biological action being defined as its ability to kill or impair the function of mammalian cells, in particular cells of the mammalian gut epithelium.
- Toxin neutralising activity of a substance may be measured by its ability to prevent the death of mammalian cells grown in culture.
- a therapeutically effective amount refers to the amount of the antibody, which when administered alone or in combination to a patient for treating CDI, or at least one of the clinical symptoms of CDI, is sufficient to affect such treatment of the disease, or symptom.
- the therapeutically effective amount can vary depending, for example, on the antibody, the infection, and/or symptoms of the infection, severity of the infection, and/or symptoms of the infection, the age, weight, and/or health of the patient to be treated, and the judgment of the prescribing physician.
- An appropriate therapeutically effective amount in any given instance may be ascertained by those skilled in the art or capable of determination by routine experimentation.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody are outweighed by the beneficial effects.
- a “prophylactically effective amount” is any amount of the antibody that, when administered alone or in combination to a patient, inhibits or delays the onset or reoccurence of the CDI, or at least one of the clinical symptoms of CDI. In some embodiments, the prophylactically effective amount prevents the onset or reoccurence of the Clostridium difficile infection entirely. "Inhibiting" the onset means either lessening the likelihood of the infection's onset, or preventing the onset entirely.
- Sheep means any species that falls within the Ovis genus (e.g. Ovis ammon, Ovis orientalis aries, Ovis orientalis orientalis, Ovis orientalis vignei, Ovis Canadensis, Ovis dalli, Ovis nivicola).
- An ovine antibody is an antibody that has at least 100%, 99%, 95%, 90%, 80%, 75%, 60%, 50%, 25% or 10% amino acid sequence identity to an antibody that has been raised in a sheep.
- sequence comparison typically one sequence acts as a reference sequence, to which test sequences may be compared.
- test and reference sequences are input into a computer, subsequent coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
- sequence comparison algorithm then calculates the percentage sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
- Optimal alignment of sequences for comparison may be conducted, for example, by the local homology alignment algorithm of Smith and Waterman [Adv. Appl. Math. 2: 484 (1981 )], by the algorithm of Needleman & Wunsch [J. Mol. Biol. 48: 443 (1970 )] by the search for similarity method of Pearson & Lipman [Proc. Nat'l. Acad. Sci. USA 85: 2444 (1988 )], by computer implementations of these algorithms ( GAP, BESTFIT, FASTA, and TFASTA - Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705 ), or by visual inspection [see Current Protocols in Molecular Biology, F.M. Ausbel et al, eds, Current Protocols, a joint venture between Greene Publishing Associates, In. And John Wiley & Sons, Inc. (1995 Supplement) Ausbubel ].
- the identity exists over a region of the sequences that is at least 10 amino acid, preferably at least 20 amino acid, more preferably at least 30 amino acid residues in length.
- an “antibody” is used in the broadest sense and specifically covers polyclonal antibodies and antibody fragments so long as they exhibit the desired biological activity.
- an antibody is a protein including at least one or two, heavy (H) chain variable regions (abbreviated herein as VHC), and at least one or two light (L) chain variable regions (abbreviated herein as VLC).
- VHC and VLC regions can be further subdivided into regions of hypervariability, termed “complementarity determining regions" (“CDR"), interspersed with regions that are more conserved, termed “framework regions” (FR).
- CDR complementarity determining regions
- FR framework regions
- each VHC and VLC is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FRI, CDRI, FR2, CDR2, FR3, CDR3, FR4.
- the VHC or VLC chain of the antibody can further include all or part of a heavy or light chain constant region.
- the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are interconnected by, e.g., disulfide bonds.
- the heavy chain constant region includes three domains, CHI, CH2 and CH3.
- the light chain constant region is comprised of one domain, CL.
- the variable region of the heavy and light chains contains a binding domain that interacts with an antigen.
- the constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
- antibody includes intact immunoglobulins of types IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof), wherein the light chains of the immunoglobulin may be of types kappa or lambda.
- antibody also refers to a portion of an antibody that binds to a toxin of C . difficile (e.g. Toxin B), e.g., a molecule in which one or more immunoglobulin chains is not full length, but which binds to a toxin.
- a toxin of C . difficile e.g. Toxin B
- a molecule in which one or more immunoglobulin chains is not full length, but which binds to a toxin e.g., a molecule in which one or more immunoglobulin chains is not full length, but which binds to a toxin.
- binding portions encompassed within the term antibody include (i) a Fab fragment, a monovalent fragment consisting of the VLC, VHC, CL and CHI domains; (ii) a F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fc fragment consisting of the VHC and CHI domains; (iv) a Fv fragment consisting of the VLC and VHC domains of a single arm of an antibody, (v) a dAb fragment ( Ward et al, Nature 341:544-546, 1989 ), which consists of a VHC domain; and (vi) an isolated complementarity determining region (CDR) having sufficient framework to bind, e.g.
- CDR complementarity determining region
- an antigen binding portion of a variable region An antigen binding portion of a light chain variable region and an antigen binding portion of a heavy chain variable region, e.g., the two domains of the Fv fragment, VLC and VHC, can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VLC and VHC regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science IAI-ATi-AI ⁇ ; and Huston et al. (1988) Proc. Natl. Acad. ScL USA 85:5879-5883 ).
- Such single chain antibodies are also encompassed within the term antibody. These are obtained using conventional techniques known to those with skill in the art, and the portions are screened for utility in the same manner as are intact antibodies.
- a C. difficile strain producing Toxinotype 0 Toxins A and B (e.g. VPI 10463) was grown in dialysis sac culture as described ( Roberts and Shone (2001) Toxicon 39: 325-333 ). After growth, the cell slurry was collected from the dialysis sacs and then centrifuged for 10000 x g for 30 min and the pH of the resulting supernatant fluid adjusted to pH 7.5 and made 70% saturated with respect to ammonium sulphate. The precipitate containing the toxins was collected by centrifugation then resuspended in 50mM bistris pH 6.5 buffer and dialysed against the same buffer at 4°C.
- Toxins A and B After dialysis, the solution of crude Toxins A and B was purified by chromatography on Q Sepharose, anion exchange chromatography and the protein peaks containing the toxins eluted with a gradient of NaCl.
- the peak containing Toxin A was dialysed against 50mM Hepes pH 7.4 buffer containing 0.5 M NaCl and purified on a Zn chelating column (Zn Sepharose). After loading the toxin and washing the contaminating proteins from the column, the purified Toxin A was eluted with a buffer containing 50 mM Hepes pH 7.4, 20 mM EDTA and 0.1M NaCl.
- the purified Toxin A was dialysed against 50mM Hepes pH 7.4 buffer containing 0.15 M NaCl and stored at 4oC or frozen until use.
- the peak containing the Toxin B from the initial Q Sepharose column was further purified by chromatography on a column of high resolution Mono Q anion exchange resin. After loading the toxin onto the column in 50mM bistris pH 6.5 buffer, the purified Toxin B was eluted with a NaCl gradient and the fractions containing the toxin pooled.
- the purified Toxin B was dialysed against 50mM Hepes pH 7.4 buffer containing 0.15 M NaCl and stored at 4oC or frozen until use.
- Toxins A and B representing any of the known Toxinotypes may be purified as described in Example 1.
- Known C. difficile strains producing Toxins A and B of various toxinotypes are given in Table 1 and by selecting the required strain for purification, Toxins A and B of the required Toxinotype may be purified.
- C. difficile may be toxinotyped as described previously ( Rupnik et al. (1998) J. Clinical Microbiol. 36: 2240-2247 ; Rupnik et al. (2001) Microbiology 147: 439-447 ) until a C. difficile strain producing toxin of the desired toxinotype is obtained
- C. difficile strain R20291 (also known as NCTC 13366) was grown in dialysis sac culture as described ( Roberts and Shone (2001) Toxicon 39: 325-333 ) and the toxins purified as described in Example 1.
- Amino acid sequences of examples of the C. difficile Toxins A and B are shown Seq IDs 1 to 4.
- Genes encoding these peptides may made commercially with codon bias for any desired expression host (e.g. E. coli, Pichia pastoris ).
- Peptides are expressed from these genes using standard molecular biology methods (e.g. Sambrook et al. 1989, Molecular Cloning a Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York ) and the resulting soluble expressed polypeptides are purified by a combination of hydrophobic interaction chromatography, ion exchange chromatography and ceramic hydroxyl apatite chromatography.
- affinity purification tags e.g. Histidine-6, streptag
- pET vector Expression System Manual 11th Edition published by Merck KGaA, Darmstadt, Germany .
- the recombinant toxin may be expressed from a synthetic gene as above.
- Amino acid sequences of the C. difficile binary toxin fragments A and B are shown Seq IDs 5 and 6, respectively.
- Genes encoding these peptides may made by commercially with codon bias for any desired expression host (e.g. E. coli, Pichia pastoris ).
- Peptides are expressed from these genes using standard molecular biology methods (e.g. Sambrook et al. 1989, Molecular Cloning a Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York ) and the resulting soluble expressed peptides are purified by a combination of hydrophobic interaction chromatography, ion exchange chromatography and ceramic hydroxyl apatite chromatography.
- chromatographic techniques well known to the art of protein purification, such as size exclusion chromatography and/or affinity chromatography, may be used.
- recombinant fragments may also be expressed with affinity purification tags (e.g Histidine-6, streptag) such as described in the pET vector Expression System Manual, 11th Edition published by Merck KGaA, Darmstadt, Germany .
- the peptides are produced in an insoluble form then they may be expressed with a histidine-6 purification tag using a commercially available expression vector such as pET52b and refolded by on-column refolding techniques as described by the review of Lia et al. and references contained therein ( Lia M et al (2004) Protein Expression & Purification 33, 1-10 ).
- Purified C. difficile toxins at a concentration of between 0.2 - 2 mg/ml are dialysed against a suitable buffer (e.g. 10mM Hepes buffer pH 7.4 containing 150mM NaCl) and then formaldehyde added at a final concentration of between 0.05 and 0.5% and incubated for between 1 and 25 days at 35°C. After incubation, the formaldehyde is removed by dialysis. Conditions for the treatment with formaldehyde may vary between peptides and final conditions may be fine-tuned on the basis of outcome of protective efficacy evaluations.
- a suitable buffer e.g. 10mM Hepes buffer pH 7.4 containing 150mM NaCl
- formaldehyde added at a final concentration of between 0.05 and 0.5% and incubated for between 1 and 25 days at 35°C. After incubation, the formaldehyde is removed by dialysis. Conditions for the treatment with formaldehyde may vary between peptides and final conditions may be fine-
- Toxins A and B from a toxinotype 0 strain were prepared as described in Example 1.
- Toxin A or B may be made by recombinant methods as described by Yang et al. ( Yang G, Zhou B, Wang J, He X, Sun X, Nie W, Tzipori S, Feng H (2008) Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol. 8: 192 ).
- Purified Toxins may be toxoided as described in Example 5.
- Example 8 Assessment of the neutralising efficacy for antisera to toxins using the in vitro cell assay
- the toxin neutralizing activity of the antisera against C. difficile Toxins is measured by cytotoxicity assays using Vero cells.
- a fixed amount of either purified C. difficile Toxin A or Toxin B is mixed with various dilutions of the antibodies, incubated for 1h at 37°C and then applied to Vero cells growing on 24-well tissue culture plates.
- Both Toxin A and B possess cytotoxic activity which results in a characteristic rounding of the Vero cells over a period of 24 - 72 h.
- neutralising antibodies this activity is inhibited and the neutralising strength of an antibody preparation may be assessed by the dilution required to neutralise the effect of a designated quantity of either Toxin A or B.
- Table 2 Data demonstrating the neutralising activity of ovine antibody to C. difficile Toxin A is shown in Table 2.
- various dilutions of ovine antibody were mixed with Toxin A at a final concentration of 50 ng/ml and incubated for 1 h at 37°C and then applied to Vero cells as above and incubated at 37° and monitored over a period of 24 -72 h.
- the antibody dilutions which protect the cells against the cytotoxic effects of the Toxin A were calculated.
- Table 2 shows that sheep immunised for a period of 14 weeks had a neutralising titre of 16000 (i.e. a 1/16000 dilution of the serum protected the cells from the cytotoxic effects of Toxin A).
- Table 2 - Neutralisation Titres of Ovine Antibodies Raised Against Formaldehyde-Treated Toxin A: Number of vaccinations Immunisation period (weeks) Antibody Neutralising Titre ⁇ 0 0 ⁇ 10 1 0 ⁇ 10 2 6 2000 3 10 4000 4 14 16000 ⁇ Dilution of serum required to neutralise 50 ng/ml of Toxin A in cell neutralisation assays
- Table 3 - Neutralisation Titres of Ovine Antibodies Raised against Formaldehyde-Treated Toxin B: These data (below) show that higher immunising doses of Toxoid B antigen results in a better ovine toxin-neutralising immune response as measured by Vero cell cytotoxicity assays.
- Example 8 Immunising dose ( ⁇ g) of C. difficile Toxoid B Neutralisation titre against Toxin B in cell assays ⁇ Sheep anti toxoid B (10ug) 1/1280 Sheep anti toxoid B (50ug) 1/2560 Sheep anti toxoid B (250ug) 1/10240 All animals were given 2 doses of formaldehyde-treated Toxin B ⁇ Dilution of serum required to completely neutralise 0.5 ng/ml of Toxin B in cell neutralisation assays
- Toxin B Toxinotype 0
- Toxinotype V Toxin B and Toxin B (Toxinotype V) were purified from C. difficile strains VPI 10463 and a C. difficile ribotype 078 isolate, respectively.
- Example 9 Quantifying the amount of specific antibody to C. difficile toxins in serum using immunoaffinity columns
- CNBr-activated Sepharose 4 Fast Flow (0.5 g dry weight) is weighed into a suitable clean container (glass or plastic). About 10 ml of diluted hydrochloric acid (1mM) is added to swell the gel and, after 20-30 min, the gel is transferred to a 10-mL glass column and washed with a further 20mL of HCI (1mM), followed by 20mL of coupling buffer (sodium bicarbonate, 100mM, pH 8.3, containing 500mM sodium chloride).
- coupling buffer sodium bicarbonate, 100mM, pH 8.3, containing 500mM sodium chloride.
- Toxin (Toxin A, Toxin B or a binary toxin fragment solution (1mL) at a concentration of 1 mg/mL is diluted to 5mL with coupling buffer and added to the column containing the activated gel and the contents mixed gently until the gel is re-suspended and rotated at room temperature overnight (16-18hr). The column is then drained and 5ml of blocking reagent (ethanolamine solution, 1M) added, mixed gently and rotated for 2hr at room temperature. Next, the column is washed with 20mL coupling buffer followed by 20mL of elution buffer (glycine solution 100mM, pH 2.5). This step is repeated twice.
- blocking reagent ethanolamine solution, 1M
- assay buffer sodium phosphate buffer, 10mM, pH 7.4 containing 500mM sodium chloride and sodium azide at a final concentration of 1g/L
- assay buffer sodium phosphate buffer, 10mM, pH 7.4 containing 500mM sodium chloride and sodium azide at a final concentration of 1g/L
- the specific binding and non-specific capacity of the column must be assessed prior to use.
- the column is removed from the refrigerator and allowed to equilibrate to room temperature and then washed with 25mL of assay buffer.
- Increasing volumes of the product (whole antisera, purified IgG, Fab or F(ab') 2 ) are individually loaded onto the column and mixed end-over-end gently for 1hr at room temperate.
- the unbound fraction is washed off with 25mL of assay buffer and the bound fraction then eluted from the column with 20 ml of elution buffer (glycine buffer 100mM, pH 2.5).
- the protein content of the eluted fraction is determined spectrophotometrically at 280nm using an extinction coefficient relevant to the product namely 1.5 for sheep IgG (Curd et al., 1971) or 1.4 for sheep Fab and F(ab') 2 (Allen, 1996).
- a saturation curve is obtained by plotting the amount of eluted protein against the volume loaded.
- Non-specific binding is assessed using normal sheep serum (NSS) prior to immunisation. Thus it is necessary to differentiate between this and binding due to some specific antibodies in normal serum (since all animals will have been exposed to C. difficile).
- Figure 1 demonstrates the typical binding capacity curve showing an increase in specific binding as a result of increasing the antiserum loading volume. There is a little change in non-specific binding (NSB) with the increase of loading volume.
- the 0.5 g (1.5-2.0 mL swelled gel) contain 1mg of toxin (coupling ratio of 2mg/g) is sufficient for the volume of specific antisera (0.5-4mL) loaded. However 1ml is the recommended loading volume for easy and convenient calculations.
- the coefficient of variation for 10 replicates is approximately 6%. There is no decline in the column capacity with time (estimated when used 80-100 times). This indicates that there is no leaching of the toxin from the column.
- the column is used for GMP/GLP assessment of in-process and final product viz whole antisera, purified IgG, Fab and F(ab') 2. It is also used to assess and monitor the immune response of the immunised animals and to detect antitoxin antibodies in human samples.
- the column is removed from the refrigerator and allowed to equilibrate to room temperature when it is washed with 25mL of assay buffer.
- Product (1mL) is added to the column and mixed end-over-end gently for 1hr at room temperature following which the unbound fraction is washed off with 25mL of assay buffer (sodium phosphate buffer, 10mM, pH 7.4 containing 500mM sodium chloride and sodium azide at a final concentration of 1g/L).
- the bound fraction is then eluted with 20 ml of elution buffer (glycine buffer 100mM, pH 2.5) and its protein content determined spectrophotometrically at 280nm using an extinction coefficient relevant to the product.
- Figure 2 shows the analysis of serum from sheep immunised with a toxoid of Toxin A.
- Antibodies will be blended to form the final product such that the required neutralising activities against Toxins A and B and their various isoforms (toxinotypes) are present in the final mixture.
- Antibodies prepared against the various C. difficile toxinotypes may be blended in order to provide similar cross-protective efficacy as assessed in Example 10.
- antibodies may be mixed in a various proportions (e.g. 1:1, 2:1, 1:2 ratios) in order to provide similar specific neutralising activity against each of the Toxin B toxinotypes.
- Three examples serve to illustrate the therapeutic value of the systemic ovine products in patients with differing degrees of seventy in their CDI.
- Example 15 Protection from CDI by passive immunisation with ovine anti-Clostridium difficile Toxins A or B antibodies, or with ovine anti- Clostridium difficile Toxins A and B antibody mixture
- Example 16 Protection from CDI induced by the 027 Ribotype, 'hypervirulent' Clostridium difficile (strain R20291, Stoke Mandeville) by passive immunisation with ovine anti-Clostridium difficile Toxins A and B mixture
- Example 17 Protection from CDI induced by the 078 Ribotype, 'hypervirulent' Clostridium difficile isolate by passive immunisation with ovine anti-Clostridium difficile Toxins A and B mixture
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
- The present invention relates to ovine antibodies and their use in the prevention or treatment of Clostridium difficile infection (CDI).
- Clostridium difficile infection (CDI) is now a major problem in hospitals worldwide. The bacterium causes nosocomial, antibiotic-associated disease which manifests itself in several forms ranging from mild self-limiting diarrhoea to potentially life-threatening, severe colitis. Elderly patients are most at risk from these potentially life-threatening diseases and incidents of CDI have increased dramatically over the last 10 years. In 2007 in the UK there were over 50,000 cases of CDI with over 8,000 associated deaths. CDI costs the NHS >£500M per annum.
- The various strains of C. difficile may be classified by a number of methods. One of the most commonly used is polymerase chain reaction (PCR) ribotyping in which PCR is used to amplify the 16S-23S rRNA gene intergenic spacer region of C. difficile. Reaction products from this provide characteristic band patterns identifying the bacterial ribotype of isolates. Toxinotyping is another typing method in which the restriction patterns derived from DNA coding for the C. difficile toxins are used to identify strain toxinotype. The differences in restriction patterns observed between toxin genes of difference strains are also indicative of sequence variation within the C. difficile toxin family. Toxin B shows sequence variation in some regions. For example, there's an approximate 13% sequence difference with the C-terminal 60kDa region of
toxinotype 0 Toxin B compared to the same region in toxinotype III. Although such sequence differences are relatively small, they can be extremely important with respect to the antigenic properties of the molecule and can have a profound impact on antibody binding and hence the toxin-neutralisation properties by antibodies. - Strains of C. difficile produce a variety of virulence factors, notable among which are several protein toxins: Toxin A, Toxin B and, in some strains, a binary toxin which is similar to Clostridium perfringens iota toxin. Toxin A is a large protein cytotoxin/enterotoxin which plays a role in the pathology of infection and may influence in the gut colonisation process. Outbreaks of CDI have been reported with Toxin A-negative/Toxin B-positive strains which suggests that Toxin B is also capable of playing a key role in the disease pathology. Both Toxins A and B exert their mechanisms of action via multi-step mechanisms which include binding to receptors on the cell surface, internalisation followed by translocation and release of the effector domain into the cell cytosol and finally intracellular action. For both Toxins A and B this involves the inactivation of small GTPases of the Rho family. For this inactivation, each toxin catalyses the transfer of a glucose moiety (from UDP-glucose) onto an amino residue of the Rho protein. Both Toxins A and B also contain a second enzyme activity in the form of a cysteine protease which appears to play a role in the release of the effector domain into the cytosol after translocation. The C. difficile binary toxin works in a different way, modifying cell actin by a mechanism which involves the transfer of an ADP-ribose moiety from NAD onto its target protein.
- Treatment of C. difficile infection currently relies on antibiotics of which metronidazole and vancomycin constitute the treatment of choice. However, these antibiotics are not effective in all cases and 20-30% of patients suffer relapse of the disease. Of major concern is the appearance in the UK of more virulent strains which were first identified in Canada in 2002. These strains, which belong to PCR ribotype 027, toxinotype III, cause CDI with a directly attributable mortality more than 3-fold that observed previously.
- Whilst
WO2006/121422 mentions goat antibodies against C. difficle toxins and uses thereof new therapeutics are required especially urgently since the efficacy of current antibiotics appears to be decreasing. - Accordingly, there is a need in the art for new therapies/therapeutics capable of specifically addressing C. difficile infection (CDI). This need is addressed by the present invention, which solves one or more of the above-mentioned problems.
- The invention is defined according to the claims.
- The present invention provides ovine polyclonal antibodies, for use as defined according to the claims.
- In use, the antibodies of the invention bind a C. difficile toxin or a fragment thereof and neutralise the biological activity of the toxin or fragment thereof. Accordingly, the antibodies of the present invention are capable of preventing or treating CDI, and preferably also preventing a relapse in a patient.
- The antibodies of the present invention provide a distinct advantage over other therapeutics in that they are able to inhibit the biological action of one or more of the toxins of C. difficile, whilst having a low immunogenic effect on a patient. Moreover, the antibodies of the present invention can be produced in high titres. Thus, the ovine antibodies can be readily obtained and can protect and/ or the patient against the pathological effects produced by C. difficile with minimal side-effects. The antibodies of the present invention may also be utilised in the development of a vaccine for passive immunization against CDI. The antibody composition of the present invention comprises ovine antibodies that bind to and neutralise C. difficile Toxin A (or a fragment thereof) and to C. difficile Toxin B (or a fragment thereof).
- The antibody composition of the present invention may also comprise ovine antibodies that bind to and/or neutralise C. difficile Binary Toxin (or a fragment thereof).
- In one embodiment, the antibody composition comprises a first antibody that binds to and neutralises C. difficile Toxin A (or a fragment thereof), and a second antibody antibody that binds to and neutralises C. difficile Toxin B (or a fragment thereof), and optionally includes a third antibody that binds to and/ or neutralises C. difficile Binary Toxin (or a fragment thereof).
- In another embodiment, the antibody composition comprises a first antibody that binds to and neutralises C. difficile Toxin B (or a fragment thereof), and a second antibody that binds to and neutralises C. difficile Toxin A (or a fragment thereof), and optionally includes a third antibody that binds to and/ or neutralises C. difficile Binary Toxin (or a fragment thereof).
- An antibody of the invention may specifically bind and neutralise one of C. difficile Toxin A (or a fragment thereof) or C. difficile Toxin B (or a fragment thereof).
- The antibodies of the present invention interact with specific epitopes of the toxin. For example, an antibody can bind an epitope in the N-terminal domain (e.g. between amino acids 1-957) or the mid-region domains (e.g. between amino acids 958-1831) or the C-terminal repeat domains (e.g. between amino acids 1832-2710) of C. difficile Toxin A. For example, the antibody may bind to an epitope within amino acids 1832-2710 of C. difficile Toxin A. Similarly an antibody can bind an epitope in the N-terminal domain (e.g. between amino acids 1-955) or the mid-region domains (e.g. between amino acids 956-1831) or the C-terminal repeat domains (e.g. between amino acids 1832-2366) of Toxin B. For example, an antibody may bind to an epitope within amino acids 1832-2366 of Toxin B. In the case of the binary toxin antibodies may bind to the catalytic domain (Fragment A) or the receptor binding domain, which resides in the C-terminal portion of Fragment B (approx residues 400-870); and/ or to the N-terminal half of Fragment B (approx residues 1-400), which is involved in the binding and translocation of Fragment A into the cell.
- In one embodiment, the C. difficile toxin is selected from one of
toxinotypes 0 to XV. Preferred toxinotypes (plus example Ribotypes and Strains) are listed in Table 1 immediately below. The listed toxinotypes are purely illustrative and are not intended to be limiting to the present invention.Table 1 Toxinotype Example Ribotypes Example Strains Reference 0 001, 106 VPI10463 I 003, 012, 102 EX623 II 103 AC008 Rupnik et al. (1998) III 027, 034, 075, 080 R20291, QCD-32g58 IV 023, 034, 075, 080 55767 J. Clinical Microbiol. V 066, 078 SE881 VI 045, 063, 066 51377 36: 2240-2247 VII 063 57267 VIII 017, 047 1470 IX 019 51680 X 036 8864 XI 033 IS58, R11402 Rupnik et al. (2001) XII 056 IS25 XIII 070 R9367 Microbiology XIV 111 R10870 XV 122 R9385 147: 439-447 - Different antibodies of the present invention may bind to and neutralise the same or different strains of C. difficile toxin. For example, the antibodies may bind to and neutralise one or more of the following: C. difficile Toxin A -
Toxinotype 0; C. difficile Toxin B -Toxinotype 0; C. difficile Toxin A - Toxinotype III; C. difficile Toxin B - Toxinotype III; C. difficile Toxin A - Toxinotype V; and/or C. difficile Toxin B - Toxinotype V. Preferably, a mixture of antibodies is employed, which bind to and neutralise Toxins A and B from all of these Toxinotypes. An antibody of the present invention may bind to an epitope in the N-terminal domain, the mid-region domain, and/or the C-terminal repeat domain of said strains of C. difficile Toxin A and/or C. difficile Toxin B. - In certain embodiments, the antibodies of the present invention may bind to and neutralise at least one C. difficile toxin comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99%, or more identical to SEQ ID NOs: 1-6, or a fragment thereof.
- The patient can be infected with C. difficile, or have a symptom of C. difficile (e.g. mild self-limiting diarrhoea, abdomen pain, fever and loss of appetite to life-threatening conditions such as pseudomembranous colitis and cytotoxic megacolon) or have a predisposition towards C. difficile infection (e.g. undergoing treatment with antibiotics, having experienced C. difficile and at risk of relapse, or exposed to a second individual who has shown the clinical symptoms associated with C. difficile infection). The present invention thereby provides an effective means for preventing or treating CDI.
- The antibody composition for use according to the present invention may be administered to a patient infected with C. difficile, or suffering from the symptoms of CDI. This can be accomplished using a therapeutically effective amount of the antibodies. Such administration may be effected by repeated administrations of antibody compositions of the present invention, for a prolonged period of time. The antibody components of said compositions may be the same or different (in terms of their toxinotype specificity and/ or targeted binding region or epitope on a C. difficile Toxin), and administration can be concurrent or sequential, and can be effected in any order.
- In another embodiment, the antibodies for use according to the invention provide passive immunity against CDI. This can be accomplished using a prophylactically effective amount of the antibodies prior to the onset or in the very early stages of CDI. Such administration may be effected by repeated administrations of antibody compositions of the present invention, for a prolonged period of time. The antibody components of said compositions may be the same or different (in terms of their toxinotype specificity and/ or targeted binding region or epitope on a C. difficile Toxin), and administration can be concurrent or sequential, and can be effected in any order.
- The ovine antibodies are antibodies which have been raised in a sheep. Thus, the present invention includes a method of producing ovine polyclonal antibodies for use according to the invention, said method generally involving (i) administering an immunogen comprising a C. difficile toxin or a fragment thereof to a sheep, (ii) allowing sufficient time for the generation of antibodies in the sheep, and (iii) obtaining the antibodies from the sheep. As used herein, sheep comprise any species that fall within the Ovis genus (e.g. Ovis ammon, Ovis orientalis aries, Ovis orientalis orientalis, Ovis orientalis vignei, Ovis Canadensis, Ovis dalli, Ovis nivicola).
- The present invention also includes a method of producing ovine antibodies for use in the antibody composition of the invention, wherein the ovine antibodies are elicited by a sheep in response to an immunogen comprising a C. difficile toxin or a fragment thereof (preferably a fragment that possesses antigenic cross-reactivity with the full-length natural Toxin and/ or retains the toxin or toxin-like activity of the full-length natural Toxin).
- The antibody may be obtained from the sheep serum. Thus, the procedures generate sheep antisera containing antibodies capable of binding and neutralising C. difficile toxins. In a further embodiment, the antibodies are isolated and/or purified. Thus, another aspect of the present invention involves purifying the antibodies from sheep antiserum.
- In one embodiment, the immunogen used to generate the antibodies of the present invention is a C. difficile toxin or a fragment thereof, which has optionally been purified. Suitable C. difficile toxins include any C. difficile toxins that cause or are associated with CDI or a symptom thereof. In a further embodiment, the toxin is selected from at least one of the following toxins: C. difficile Toxin A or a fragment thereof, C. difficile Toxin B or a fragment thereof and C. difficile Binary Toxin or a fragment thereof. The C. difficile toxin may also be a toxin selected from one of the
toxinotypes 0 to XV as defined hereinbefore. - Production of a purified C. difficile toxin is exemplified in the Examples. In certain embodiments, the immunogen is a C. difficile toxin variant. In another embodiment the immunogen comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99%, or more identical to SEQ ID NOs: 1-6, or a fragment thereof.
- The immunogen used to generate the antibodies of the present invention may also be partially or completely inactivated, i.e. have reduced toxicity. Examples of modification include: chemical treatment (e.g. treatment with UDP-dialdehyde, formaldehyde, glutaraldehyde, peroxide, or oxygen) and recombinant methods (e.g. deletions or mutations in the toxin). For example, the immunogen may be a C. difficile toxoid or a fragment thereof derived from the native toxin by treatment with formaldehyde. Alternatively, a recombinant toxoid may be generated by selectively inactivating the active site motif by site-directed mutagenesis. An example of site directed mutagenesis to reduce or ablate the toxin effects of Toxins A and B is modification of the DXD motif in the N-terminal domain of the toxin. The aspartates and/or other residues may be mutated to e.g. alanine in order to reduce the biological activity of either Toxin A and B. For example, for Toxin A one of more of the following amino acids may be mutated: Asp 269, Asp285, Asp 287, Asn383, Trp519, Tyr283, Arg272. For Toxin B one of more of the following amino acids may be mutated: Asp270, Asp286, Asp 288, Asn384, Trp520, Tyr284, Arg273.
- Antigens may be formulated with an adjuvant. Suitable adjuvants may include alum (aluminium phosphate or aluminium hydroxide), which is used widely in humans, and other adjuvants such as saponin and its purified component Quil A, Freund's complete adjuvant, RIBBI adjuvant, and other adjuvants used in research and veterinary applications.
- The C. difficile toxins or toxoids may be used as immunogens separately or in combination, either concurrently or sequentially, in order to produce antibodies specific for individual C. difficile toxins or combinations. For example, two or more toxins or toxoids may be mixed together and used as a single immunogen. Alternatively a C. difficile toxin (e.g. C. difficile Toxin A) may be used separately as a first immunogen on a first sheep, and another C. difficile toxin (e.g. C. difficile Toxin B) may be used separately on a second sheep. The antibodies produced by separate immunisation may be combined to yield an antibody composition directed against C. difficile toxins.
- The method comprises all modes of immunisation, including subcutaneous, intramuscular, intraperitoneal, and intravenous. The invention also contemplates a wide variety of immunisation schedules. In one embodiment, a sheep or goat is administered toxin(s) on day zero and subsequently receives toxin(s) at intervals thereafter. It will be appreciated that the interval range and dosage range required depends on the precise nature of the immunogen, the route of administration, the nature of the formulation, and the judgement of the attending person. Variations in these dosage levels can be adjusted using standard empirical routines for optimisation. Similarly, it is not intended that the present invention be limited to any particular schedule for collecting antibody. The preferred collection time is someday after day 56. Levels of the specific antibody, i.e. that which binds to the immunogen, should represent at least 3 g per litre of serum.
- The antibodies of the invention may be modified as necessary after collection, so that, in certain instances, they are less immunogenic in the patient to whom they are administered. For example, if the patient is a human, the antibodies may be despeciated by methods well known in the art. One example as to how an antibody can be made less immunogenic is to prepare the (Fab)2 fragment. The antibodies of the invention may be used to produce such antibody fragments for which various techniques have been developed. For example, the fragments may be derived by proteolytic digestion of intact antibodies. Other techniques for their production will be apparent to the skilled practitioner.
- In use, the present invention employs a pharmaceutical composition, comprising the antibody composition of the present invention in a form suitable for parenteral, usually intravenous administration. The purified intact antibodies, or their fragments, are formulated for such delivery. For example, antibody, or its fragment, at a concentration between 5-50 or 15-50 or 25-50 g/litre may be formulated in buffer. Examples of suitable buffer components include physiological salts such as sodium citrate and/ or citric acid. Preferred buffers contain 100-200 or 125-175 or approximately 150 (eg. 153) mM physiological salts such as sodium chloride. Preferred buffers maintain the pharmaceutical composition at a pH that is close to the physiological pH of the patient - for example, at a pH of 5.5-6.4, or at a pH of 5.6-6.3, or at a pH of 5.7-6.2, or at a pH of 5.8-6.2. The antibody-containing compositions of the present invention preferably exclude adjuvant(s) as it is undesirable to stimulate an immune response against said antibodies in the patient.
- Antibodies of the invention may be formulated for, but not limited to intramuscular, subcutaneous or intravenous delivery. Compositions suitable for intramuscular, subcutaneous or intravenous injection include sterile aqueous solutions. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The antibody compositions of the present invention are not oral formulations, and this mode of administration is not employed. In this regard, a key problem with oral delivery is ensuring that sufficient antibody reaches the colon where it is required. Factors which prevent antibody reaching the gut include the proteolytic enzymes present in the digestive secretions, which degrade the antibody molecule and also in some instances the effect of CDI itself which can cause paralytic ileus and other complications that prevent movement of fluids down the alimentary canal.
- Compositions suitable for injection may be in the form of solutions, suspensions or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
- In preparing solutions of the antibodies or their fragments can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal or suspending and/or local anaesthetic agents may be dissolved in the vehicle.
- Dry powders, which are dissolved or suspended in a suitable vehicle prior to use, may be prepared by filling pre-sterilised ingredients into a sterile container using aseptic technique in a sterile area. Alternatively the ingredients may be dissolved into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
- The dosage ranges for administration of the antibodies of the present invention are those to produce the desired therapeutic effect. It will be appreciated that the dosage range required depends on the precise nature of the antibody or composition, the route of administration, the nature of the formulation, the age of the patient, the nature, extent or severity of the patient's condition, contraindications, if any, and the judgement of the attending physician. Variations in these dosage levels can be adjusted using standard empirical routines for optimisation.
- Suitable daily dosages are in the range of 5-20mg per kg of body weight. The unit dosage can vary from less than 100mg, but typically will be in the region of 250-2000 mg per dose, which may be administered daily or less frequently (e.g. on alternative days for up to 1 week)
It is also within the scope of the invention to use the antibodies of the invention in therapeutic methods for the prevention or treatment of CDI in combination with one another, or as an adjunct to, or in conjunction with, other established therapies normally used in the treatment in CDI. For example, the antibodies of the present invention may be administered in conjunction with a suitable antibiotic (e.g. metronidazole and/or vancomycin) - The combination treatment may be carried out in any way as deemed necessary or convenient by the person skilled in the art and for the purpose of this specification, no limitations with regard to the order, amount, repetition or relative amount of the compounds to be used in combination is contemplated.
- Clostridium difficile is a species of Gram-positive bacteria of the genus Clostridium.
- Clostridium difficile infection (CDI) means a bacterial infection which affects humans and animals and which results in a range of symptoms from mild self-limiting diarrhoea to life-threatening conditions such as pseudomembranous colitis and cytotoxic megacolon. In this disease, C. difficile replaces the normal gut flora and produces cytotoxins which attack and damage the gut epithelium. Primary risk factors for human CDI include: receiving broad-spectrum antibiotics, over 65 years old and hospitalised.
- Clostridium difficile Toxin A is a family of protein cytotoxins/enterotoxins of approximately 300 kDa in size. Toxin A has an enzyme activity within the N-terminal region which acts to disrupt the cytoskeleton of the mammalian cell causing cell death. There are a number of naturally occurring variants of Toxin A within the strains of Clostridium difficile which are call 'toxinotypes'. The various toxinotypes of Toxin A have variations within their primary sequence of usually <10% overall. Examples of suitable Toxin A sequences include SEQ ID Nos: 1 and 3.
- Clostridium difficile Toxin B is a family of protein cytotoxins of approximately 270 kDa in size which are similar to Toxin A but significantly more cytotoxic. Like Toxin A, Toxin B has an enzyme activity within the N-terminal region which acts to disrupt the cytoskeleton of the mammalian cell causing cell death. There are a number of naturally occurring variants of Toxin B within the strains of C. difficile which are call 'toxinotypes'. The various toxinotypes of Toxin B have variations within their primary sequence of usually <15% overall. Examples of suitable Toxin A sequences include SEQ ID Nos: 2 and 4.
- Binary Toxin is a two component cytotoxin produced by some but not all strains of C. difficile. The binary toxins are similar in action to Clostridium botulinum C2 and Clostridium perfringens iota toxins, which like C. difficile binary toxin, consist of a cell binding fragment of approximately 100 kDa and an enzymically active 'effector' fragment of approx. 50 kDa. Examples of suitable Binary Toxin sequences include SEQ ID Nos: 5 and 6.
- As used herein, the term "toxin" encompasses said toxin fragments. The fragment may range from any number of amino acids between 10 and 2700 (e.g. at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 750, 1000, 1500, 2000 or 2500) of the reference toxin. The fragment preferably includes at least one epitope of the gene product in question. The "fragment" may also have a common antigenic cross-reactivity and/or substantially the same in vivo biological activity as the toxin from which it is derived. For example, an antibody capable of binding to a fragment would be also capable of binding to the toxin from which it is derived. Alternatively, the fragment may share a common ability to induce a "recall response" of a T-lymphocyte which has been previously exposed to an antigenic component of a C. difficile toxin.
- Reference to the term Toxin embraces "variants" thereof - for example, a peptide or peptide fragment having at least 80 or 85 or 90 or 95 or 96 or 97 or 98 or 99 percent amino acid sequence homology with a C. difficile Toxin. In a further embodiment, a "variant" may be a mimic of the peptide or peptide fragment, which mimic reproduces at least one epitope of the peptide or peptide fragment.
- Reference to the Toxin embraces Toxin "toxoid", which is discussed in more detail below.
- Toxinotypes are often used to classify strains of C. difficile. Toxinotypes are based on a method which characterises the restriction patterns obtained with the toxin genes. As described above, toxinotypes of Toxins A and B represent variants, by primary amino acid sequence, of these protein toxins.
- Clostridium difficile Toxoid is used to describe a C. difficile toxin (Toxin A, Toxin B or Binary Toxin) or a mixture of C. difficile toxins that has been partially or completely inactivated. A toxin is considered inactivated if it has less toxicity (e.g. 100%, 99%, 95% or 90% less toxicity) than untreated toxin as measured by an in vitro cytotoxicity assay or by animal toxicity.
- An antibody that binds to a toxin of interest is one capable of binding that toxin with sufficient affinity such that the antibody is useful as a therapeutic agent. An antibody that binds to a toxin of interest is one that binds to a toxin of C. difficile with an affinity (Ka) of at least 104 M.
- Toxin neutralising means the action of a substance (e.g. an antibody) which blocks the biological action of one or more of the cytotoxins (Toxin A and/or Toxin B and/or binary toxin) of C. difficile. The cytotoxin's biological action being defined as its ability to kill or impair the function of mammalian cells, in particular cells of the mammalian gut epithelium. Toxin neutralising activity of a substance may be measured by its ability to prevent the death of mammalian cells grown in culture.
- A therapeutically effective amount refers to the amount of the antibody, which when administered alone or in combination to a patient for treating CDI, or at least one of the clinical symptoms of CDI, is sufficient to affect such treatment of the disease, or symptom. The therapeutically effective amount can vary depending, for example, on the antibody, the infection, and/or symptoms of the infection, severity of the infection, and/or symptoms of the infection, the age, weight, and/or health of the patient to be treated, and the judgment of the prescribing physician. An appropriate therapeutically effective amount in any given instance may be ascertained by those skilled in the art or capable of determination by routine experimentation. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody are outweighed by the beneficial effects.
- A "prophylactically effective amount" is any amount of the antibody that, when administered alone or in combination to a patient, inhibits or delays the onset or reoccurence of the CDI, or at least one of the clinical symptoms of CDI. In some embodiments, the prophylactically effective amount prevents the onset or reoccurence of the Clostridium difficile infection entirely. "Inhibiting" the onset means either lessening the likelihood of the infection's onset, or preventing the onset entirely.
- Sheep means any species that falls within the Ovis genus (e.g. Ovis ammon, Ovis orientalis aries, Ovis orientalis orientalis, Ovis orientalis vignei, Ovis Canadensis, Ovis dalli, Ovis nivicola).
- An ovine antibody is an antibody that has at least 100%, 99%, 95%, 90%, 80%, 75%, 60%, 50%, 25% or 10% amino acid sequence identity to an antibody that has been raised in a sheep.
- For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences may be compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequent coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percentage sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
- Optimal alignment of sequences for comparison may be conducted, for example, by the local homology alignment algorithm of Smith and Waterman [Adv. Appl. Math. 2: 484 (1981)], by the algorithm of Needleman & Wunsch [J. Mol. Biol. 48: 443 (1970)] by the search for similarity method of Pearson & Lipman [Proc. Nat'l. Acad. Sci. USA 85: 2444 (1988)], by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA - Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705), or by visual inspection [see Current Protocols in Molecular Biology, F.M. Ausbel et al, eds, Current Protocols, a joint venture between Greene Publishing Associates, In. And John Wiley & Sons, Inc. (1995 Supplement) Ausbubel].
- Examples of algorithms suitable for determining percent sequence similarity are the BLAST and BLAST 2.0 algorithms [see Altschul (1990) J. Mol. Biol. 215: pp. 403-410; and "http://www.ncbi.nlm.nih.gov/" of the National Center for Biotechnology Information].
- In a preferred homology comparison, the identity exists over a region of the sequences that is at least 10 amino acid, preferably at least 20 amino acid, more preferably at least 30 amino acid residues in length.
- An "antibody" is used in the broadest sense and specifically covers polyclonal antibodies and antibody fragments so long as they exhibit the desired biological activity. In particular, an antibody is a protein including at least one or two, heavy (H) chain variable regions (abbreviated herein as VHC), and at least one or two light (L) chain variable regions (abbreviated herein as VLC). The VHC and VLC regions can be further subdivided into regions of hypervariability, termed "complementarity determining regions" ("CDR"), interspersed with regions that are more conserved, termed "framework regions" (FR). The extent of the framework region and CDRs has been precisely defined (see, Kabat, E.A., et al. Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, 1991, and Chothia, C. et al, J. Mol. Biol. 196:901-917, 1987).
- Preferably, each VHC and VLC is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FRI, CDRI, FR2, CDR2, FR3, CDR3, FR4.
- The VHC or VLC chain of the antibody can further include all or part of a heavy or light chain constant region. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are interconnected by, e.g., disulfide bonds. The heavy chain constant region includes three domains, CHI, CH2 and CH3. The light chain constant region is comprised of one domain, CL. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. The term "antibody" includes intact immunoglobulins of types IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof), wherein the light chains of the immunoglobulin may be of types kappa or lambda.
- The term antibody, as used herein, also refers to a portion of an antibody that binds to a toxin of C. difficile (e.g. Toxin B), e.g., a molecule in which one or more immunoglobulin chains is not full length, but which binds to a toxin. Examples of binding portions encompassed within the term antibody include (i) a Fab fragment, a monovalent fragment consisting of the VLC, VHC, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fc fragment consisting of the VHC and CHI domains; (iv) a Fv fragment consisting of the VLC and VHC domains of a single arm of an antibody, (v) a dAb fragment (Ward et al, Nature 341:544-546, 1989), which consists of a VHC domain; and (vi) an isolated complementarity determining region (CDR) having sufficient framework to bind, e.g. an antigen binding portion of a variable region. An antigen binding portion of a light chain variable region and an antigen binding portion of a heavy chain variable region, e.g., the two domains of the Fv fragment, VLC and VHC, can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VLC and VHC regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science IAI-ATi-AIβ; and Huston et al. (1988) Proc. Natl. Acad. ScL USA 85:5879-5883). Such single chain antibodies are also encompassed within the term antibody. These are obtained using conventional techniques known to those with skill in the art, and the portions are screened for utility in the same manner as are intact antibodies.
- There now follows a brief description of the Figures, which illustrate aspects and/ or embodiments of the present invention.
-
Figure 1 Measurement of antibodies to Toxin A in serum by affinity chromatography. Antibody binding to Toxin A immobilised onto Sepharose gel which was subsequently eluted. The Figure shows the linear relationship between serum load and eluted Toxin A-specific antibody. Experimental details are provided in Example 9. -
Figure 2 Measurement of antibodies to Toxin A in serum by affinity chromatography. Antibody binding to Toxin A immobilised onto Sepharose gel which was subsequently eluted. The Figure demonstrates specific antibody in sheep immunised with a toxoid of Toxin A. Antibodies to Toxin A were present in the sheep serum at >3 mg/ml (3 g/litre). Experimental details are provided in Example 9. -
Figure 3 Protection from CDI by passive immunisation with ovine anti Clostridium difficile Toxins A and B mixture. Syrian hamsters (groups of 10) were passively immunised (i.p.) with either ovine antibodies to Toxin A and B at 10 mg/dose (▼), 2 mg/dose (■) or with a non-specific control antibody (●) at the times indicated. Animals received clindamycin at Day -2 and atDay 0 were challenged with C. difficile spores (2 x102 colony forming units). Survival, days post challenge are shown by the plots. -
Figure 4 Protection from CDI by passive immunisation with ovine anti Clostridium difficile Toxins A or B. Syrian hamsters (groups of 10) were passively immunised (i.p.) with either ovine antibodies to Toxin A + B at 10 mg/dose (▼), Toxin A antibodies alone at 10 mg/dose (Δ), Toxin B antibodies alone at 10 mg/dose (○) or with a non-specific control antibody (□) at the times indicated. Animals received clindamycin at Day -2 and atDay 0 were challenged with C. difficile spores (2 x102 colony forming units). Survival, days post challenge are shown by the plots. -
Figure 5 Protection from CDI induced by the 027 Ribotype, 'hypervirulent' Clostridium difficile (strain R20291, Stoke Mandeville) by passive immunisation with ovine anti Clostridium difficile Toxins A and B mixture. Syrian hamsters (groups of 10) were passively immunised (i.p.) with either ovine antibodies to Toxin A and B at 10 mg/dose (▼) or with a non-specific control antibody (■) at the times indicated. Animals received clindamycin at Day -3 and atDay 0 were challenged with C. difficile spores (1 x103 colony forming units). Disease states at days post challenge are shown by the plots. -
Figure 6 Protection from CDI induced by the 078 Ribotype, 'hypervirulent' Clostridium difficile (Toxinotype 5) by passive immunisation with ovine anti Clostridium difficile Toxins A and B mixture. Syrian hamsters (groups of 10) were passively immunised (i.p.) with either ovine antibodies to Toxin A and B at 10 mg/dose (▼) or with a non-specific control antibody (●) at the times indicated. Animals received clindamycin at Day -2 and atDay 0 were challenged with C. difficile spores (2 x103 colony forming units). Disease states at days post challenge are shown by the plots. -
- Example 1 Purification of C. difficile Toxins A and B of
Toxinotype 0 - Example 2 Purification of C. difficile Toxins A and B of Other Toxinotypes
- Example 3 Purification of recombinant C. difficile Toxins A and B
- Example 4 Purification of C. difficile binary toxin
- Example 5 Preparation of Toxoids of C. difficile Toxins A and B
- Example 6 Preparation of antiserum
- Example 7 Preparation of antiserum to Toxins A and B of
toxinotype 0 - Example 8 Assessment of the neutralising efficacy for antisera to toxins using the in vitro cell assay
- Example 9 Quantifying the amount of specific antibody to C. difficile toxins in serum using immunoaffinity columns
- Example 10 Preparation of antibody mixtures
- Example 11 Assessment of the in vivo efficacy of ovine antibodies for preventing CDI
- Example 12 Assessment of the in vivo efficacy of ovine antiserum for treating CDI
- Example 13 Clinical uses of antibody formulations
- Example 14 Protection from CDI by passive immunisation with ovine anti-Clostridium difficile Toxins A and B antibody mixture
- Example 15 Protection from CDI by passive immunisation with ovine anti-Clostridium difficile Toxins A or B antibodies, or with ovine anti-Clostridium difficile Toxins A and B antibody mixture
- Example 16 Protection from CDI induced by the 027 Ribotype, 'hypervirulent' Clostridium difficile (strain R20291, Stoke Mandeville) by passive immunisation with ovine anti-Clostridium difficile Toxins A and B mixture
- Example 17 Protection from CDI induced by the 078 Ribotype, 'hypervirulent' Clostridium difficile isolate by passive immunisation with ovine anti-Clostridium difficile Toxins A and B mixture
- Where an initial Met amino acid residue or a corresponding initial codon is indicated in any of the following SEQ ID NOs, said residue/ codon is optional.
- 1. Protein sequence of Clostridium difficile Toxin A -
Toxinotype 0 - 2. Protein sequence of Clostridium difficile Toxin B -
Toxinotype 0 - 3. Protein sequence of Clostridium difficile Toxin A - Toxinotype III
- 4. Protein sequence of Clostridium difficile Toxin B - Toxinotype III
- 5. Protein sequence of Clostridium difficile Binary toxin fragment A
- 6. Protein sequence of Clostridium difficile Binary toxin fragment B
- A C. difficile
strain producing Toxinotype 0 Toxins A and B (e.g. VPI 10463) was grown in dialysis sac culture as described (Roberts and Shone (2001) Toxicon 39: 325-333). After growth, the cell slurry was collected from the dialysis sacs and then centrifuged for 10000 x g for 30 min and the pH of the resulting supernatant fluid adjusted to pH 7.5 and made 70% saturated with respect to ammonium sulphate. The precipitate containing the toxins was collected by centrifugation then resuspended in 50mM bistris pH 6.5 buffer and dialysed against the same buffer at 4°C. After dialysis, the solution of crude Toxins A and B was purified by chromatography on Q Sepharose, anion exchange chromatography and the protein peaks containing the toxins eluted with a gradient of NaCl. The peak containing Toxin A was dialysed against 50mM Hepes pH 7.4 buffer containing 0.5 M NaCl and purified on a Zn chelating column (Zn Sepharose). After loading the toxin and washing the contaminating proteins from the column, the purified Toxin A was eluted with a buffer containing 50 mM Hepes pH 7.4, 20 mM EDTA and 0.1M NaCl. The purified Toxin A was dialysed against 50mM Hepes pH 7.4 buffer containing 0.15 M NaCl and stored at 4oC or frozen until use. The peak containing the Toxin B from the initial Q Sepharose column was further purified by chromatography on a column of high resolution Mono Q anion exchange resin. After loading the toxin onto the column in 50mM bistris pH 6.5 buffer, the purified Toxin B was eluted with a NaCl gradient and the fractions containing the toxin pooled. The purified Toxin B was dialysed against 50mM Hepes pH 7.4 buffer containing 0.15 M NaCl and stored at 4oC or frozen until use. - Toxins A and B representing any of the known Toxinotypes may be purified as described in Example 1. Known C. difficile strains producing Toxins A and B of various toxinotypes are given in Table 1 and by selecting the required strain for purification, Toxins A and B of the required Toxinotype may be purified. Alternatively, C. difficile may be toxinotyped as described previously (Rupnik et al. (1998) J. Clinical Microbiol. 36: 2240-2247; Rupnik et al. (2001) Microbiology 147: 439-447) until a C. difficile strain producing toxin of the desired toxinotype is obtained
- To produce Toxinotype III Toxins A and B, C. difficile strain R20291 (also known as NCTC 13366) was grown in dialysis sac culture as described (Roberts and Shone (2001) Toxicon 39: 325-333) and the toxins purified as described in Example 1.
- Amino acid sequences of examples of the C. difficile Toxins A and B are shown
Seq IDs 1 to 4. Genes encoding these peptides may made commercially with codon bias for any desired expression host (e.g. E. coli, Pichia pastoris). Peptides are expressed from these genes using standard molecular biology methods (e.g. Sambrook et al. 1989, Molecular Cloning a Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York) and the resulting soluble expressed polypeptides are purified by a combination of hydrophobic interaction chromatography, ion exchange chromatography and ceramic hydroxyl apatite chromatography. Other chromatographic techniques well known to the art of protein purification, such as size exclusion chromatography and/or affinity chromatography, may be used. For the latter, recombinant fragments may be expressed with affinity purification tags (e.g. Histidine-6, streptag) such as described in the pET vector Expression System Manual, 11th Edition published by Merck KGaA, Darmstadt, Germany. - To produce a recombinant toxin from a C. difficile toxinotype for which the sequence is unknown, it will be necessary to first extract the DNA and derive the toxin sequence(s) by standard molecular biology methods. Once the sequence has been derived, the recombinant toxin may be expressed from a synthetic gene as above.
- Amino acid sequences of the C. difficile binary toxin fragments A and B are shown
Seq IDs - If the peptides are produced in an insoluble form then they may be expressed with a histidine-6 purification tag using a commercially available expression vector such as pET52b and refolded by on-column refolding techniques as described by the review of Lia et al. and references contained therein (Lia M et al (2004) Protein Expression & Purification 33, 1-10).
- Purified C. difficile toxins at a concentration of between 0.2 - 2 mg/ml are dialysed against a suitable buffer (e.g. 10mM Hepes buffer pH 7.4 containing 150mM NaCl) and then formaldehyde added at a final concentration of between 0.05 and 0.5% and incubated for between 1 and 25 days at 35°C. After incubation, the formaldehyde is removed by dialysis. Conditions for the treatment with formaldehyde may vary between peptides and final conditions may be fine-tuned on the basis of outcome of protective efficacy evaluations.
- A number of factors are taken into consideration during the preparation of antiserum in order to achieve the optimal humoral antibody response. These include:
- breed of animal
- choice of adjuvant
- number and location of immunisation sites
- quantity of immunogen
- number of and interval between doses
- As a result of optimising these parameters it is routine to obtain specific antibody levels in excess of 6 g/litre of serum.
- For sheep, 2 ml of buffer solution containing between 10 and 500 µg of C. difficile antigen is mixed with 2.6 ml of Freund's adjuvant. The complete form of the adjuvant is used for the primary immunisation and incomplete Freund's adjuvant for all subsequent boosts. Mixing of the adjuvant is carried out for several minutes to ensure a stable emulsion. About 4.2 ml of the antigen/adjuvant mixture is used to immunise each sheep by im injection and spread across 6 sites including the neck and all the upper limbs. This is repeated every 28 days. Blood samples are taken 14 days after each immunisation. Once adequate antibody levels are achieved, larger volumes are taken (10 ml /kg body weight) into sterile bags. The bags are rotated slowly to accelerate clotting, centrifuged for 30 min at 4500 x g and the serum removed under aseptic conditions and pooled. Any animal showing low titres to the desired C. difficile antigen is removed from the flock.
- Toxins A and B from a
toxinotype 0 strain (e.g. VPI 10463) were prepared as described in Example 1. Alternatively, Toxin A or B may be made by recombinant methods as described by Yang et al. (Yang G, Zhou B, Wang J, He X, Sun X, Nie W, Tzipori S, Feng H (2008) Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol. 8: 192). Purified Toxins may be toxoided as described in Example 5. - For immunisation of sheep with Toxoids A or B, 2 ml of buffer solution containing between 10 and 500 µg of either C. difficile Toxoids A or B was mixed with 2.6 ml of Freund's adjuvant. The complete form of the adjuvant was used for the primary immunisation and incomplete Freund's adjuvant used for all subsequent boosts. Mixing of the adjuvant was carried out for several minutes to ensure a stable emulsion. After mixing, approx 4.2 ml of the antigen/adjuvant mixture was used to immunise each sheep by im injection and spread across 6 sites including the neck and all the upper limbs. This was repeated every 28 days and serum samples collected 14 days after each immunisation. Once adequate antibody levels were achieved, larger production sample were taken (10 ml /kg body weight) into sterile bags. The bags were rotated slowly to accelerate clotting, centrifuged for 30 min at 4500 x g and the serum removed under aseptic conditions and pooled. Any animal showing low titres to either Toxins A or B was omitted from the flock.
- The toxin neutralizing activity of the antisera against C. difficile Toxins is measured by cytotoxicity assays using Vero cells. A fixed amount of either purified C. difficile Toxin A or Toxin B is mixed with various dilutions of the antibodies, incubated for 1h at 37°C and then applied to Vero cells growing on 24-well tissue culture plates. Both Toxin A and B possess cytotoxic activity which results in a characteristic rounding of the Vero cells over a period of 24 - 72 h. In the presence of neutralising antibodies this activity is inhibited and the neutralising strength of an antibody preparation may be assessed by the dilution required to neutralise the effect of a designated quantity of either Toxin A or B.
- Data demonstrating the neutralising activity of ovine antibody to C. difficile Toxin A is shown in Table 2. In this experiment, various dilutions of ovine antibody were mixed with Toxin A at a final concentration of 50 ng/ml and incubated for 1 h at 37°C and then applied to Vero cells as above and incubated at 37° and monitored over a period of 24 -72 h. The antibody dilutions which protect the cells against the cytotoxic effects of the Toxin A were calculated. Table 2 shows that sheep immunised for a period of 14 weeks had a neutralising titre of 16000 (i.e. a 1/16000 dilution of the serum protected the cells from the cytotoxic effects of Toxin A).
Table 2 - Neutralisation Titres of Ovine Antibodies Raised Against Formaldehyde-Treated Toxin A: Number of vaccinations Immunisation period (weeks) Antibody Neutralising Titre ¶0 0 <10 1 0 <10 2 6 2000 3 10 4000 4 14 16000 ¶ Dilution of serum required to neutralise 50 ng/ml of Toxin A in cell neutralisation assays Table 3 - Neutralisation Titres of Ovine Antibodies Raised Against Formaldehyde-Treated Toxin B: These data (below) show that higher immunising doses of Toxoid B antigen results in a better ovine toxin-neutralising immune response as measured by Vero cell cytotoxicity assays. The assays employed are described immediately above in Example 8. Immunising dose (µg) of C. difficile Toxoid B Neutralisation titre against Toxin B in cell assays¶ Sheep anti toxoid B (10ug) 1/1280 Sheep anti toxoid B (50ug) 1/2560 Sheep anti toxoid B (250ug) 1/10240 All animals were given 2 doses of formaldehyde-treated Toxin B
¶ Dilution of serum required to completely neutralise 0.5 ng/ml of Toxin B in cell neutralisation assays - These data (below) compare the capacity of ovine antibody raised against Toxoid B derived from Toxin B (Toxinotype 0) to neutralise equivalent amounts of Toxin B (Toxinotype 0) and Toxin B (Toxinotype III). Toxin B (Toxinotype 0) and Toxin B (Toxinotype III) were purified from C. difficile strains VPI 10463 and R20291, respectively.
- Cell assays were performed as described immediately above in Example 8 using equivalent cytotoxic amounts of each Toxin B type. Titrations were carried out on Toxin B fixed at 4 units (4 fold the amount required to induce cell death) in one experiment and 10 units in another experiment.
- The data show that the ovine antibody raised against Toxin B, using a Toxoid B derived from
Toxinotype 0 strain, neutralised Toxin B (Toxinotype 0) and Toxin B (Toxinotype III) with the same efficacy.Toxinotype Ovine anti Toxin B - Neutralisation Titre 4 units Toxin B 10 units toxin B Toxin B - Toxinotype 02560 1280 Toxin B - Toxinotype III 2560 1280 Relative titre (0:III) 1 1 - These data compare the capacity of ovine antibody raised against Toxoid B derived from Toxin B (Toxinotype 0) to neutralise equivalent amounts of Toxin B (Toxinotype 0) and Toxin B (Toxinotype V). Toxin B (Toxinotype 0) and Toxin B (Toxinotype V) were purified from C. difficile strains VPI 10463 and a C. difficile ribotype 078 isolate, respectively.
- Cell assays were performed as in Example 8 using equivalent cytotoxic amounts of each Toxin B type. Titrations were carried out on Toxin B fixed at 4 units (4 fold the amount required to induce cell death) in one experiment and 10 units in another experiment.
- The data show that the ovine antibody raised against Toxin B, using a Toxoid B derived from
Toxinotype 0 strain, neutralised Toxin B (Toxinotype 0) and also Toxin B (Toxinotype V) with 2-fold reduced efficiency.Toxinotype Ovine anti Toxin B - Neutralisation Titre 4 units Toxin B 10 units toxin B Toxin B - Toxinotype 02560 1280 Toxin B - Toxinotype V 1280 640 Relative titre (0:V) 2 2 - The required amount of CNBr-activated
Sepharose 4 Fast Flow (0.5 g dry weight) is weighed into a suitable clean container (glass or plastic). About 10 ml of diluted hydrochloric acid (1mM) is added to swell the gel and, after 20-30 min, the gel is transferred to a 10-mL glass column and washed with a further 20mL of HCI (1mM), followed by 20mL of coupling buffer (sodium bicarbonate, 100mM, pH 8.3, containing 500mM sodium chloride). Toxin (Toxin A, Toxin B or a binary toxin fragment solution (1mL) at a concentration of 1 mg/mL is diluted to 5mL with coupling buffer and added to the column containing the activated gel and the contents mixed gently until the gel is re-suspended and rotated at room temperature overnight (16-18hr). The column is then drained and 5ml of blocking reagent (ethanolamine solution, 1M) added, mixed gently and rotated for 2hr at room temperature. Next, the column is washed with 20mL coupling buffer followed by 20mL of elution buffer (glycine solution 100mM, pH 2.5). This step is repeated twice. The column is finally washed with 20mL of assay buffer (sodium phosphate buffer, 10mM, pH 7.4 containing 500mM sodium chloride and sodium azide at a final concentration of 1g/L) and stored in 3-5mL of assay buffer at 2-8°C until used. - The specific binding and non-specific capacity of the column must be assessed prior to use. The column is removed from the refrigerator and allowed to equilibrate to room temperature and then washed with 25mL of assay buffer. Increasing volumes of the product (whole antisera, purified IgG, Fab or F(ab')2) are individually loaded onto the column and mixed end-over-end gently for 1hr at room temperate. The unbound fraction is washed off with 25mL of assay buffer and the bound fraction then eluted from the column with 20 ml of elution buffer (glycine buffer 100mM, pH 2.5). The protein content of the eluted fraction is determined spectrophotometrically at 280nm using an extinction coefficient relevant to the product namely 1.5 for sheep IgG (Curd et al., 1971) or 1.4 for sheep Fab and F(ab')2 (Allen, 1996). A saturation curve is obtained by plotting the amount of eluted protein against the volume loaded.
- Non-specific binding (NSB) is assessed using normal sheep serum (NSS) prior to immunisation. Thus it is necessary to differentiate between this and binding due to some specific antibodies in normal serum (since all animals will have been exposed to C. difficile).
Figure 1 demonstrates the typical binding capacity curve showing an increase in specific binding as a result of increasing the antiserum loading volume. There is a little change in non-specific binding (NSB) with the increase of loading volume. The 0.5 g (1.5-2.0 mL swelled gel) contain 1mg of toxin (coupling ratio of 2mg/g) is sufficient for the volume of specific antisera (0.5-4mL) loaded. However 1ml is the recommended loading volume for easy and convenient calculations. - The coefficient of variation for 10 replicates (between assay CV) is approximately 6%. There is no decline in the column capacity with time (estimated when used 80-100 times). This indicates that there is no leaching of the toxin from the column.
- The column is used for GMP/GLP assessment of in-process and final product viz whole antisera, purified IgG, Fab and F(ab')2. It is also used to assess and monitor the immune response of the immunised animals and to detect antitoxin antibodies in human samples.
- The column is removed from the refrigerator and allowed to equilibrate to room temperature when it is washed with 25mL of assay buffer. Product (1mL) is added to the column and mixed end-over-end gently for 1hr at room temperature following which the unbound fraction is washed off with 25mL of assay buffer (sodium phosphate buffer, 10mM, pH 7.4 containing 500mM sodium chloride and sodium azide at a final concentration of 1g/L). The bound fraction is then eluted with 20 ml of elution buffer (glycine buffer 100mM, pH 2.5) and its protein content determined spectrophotometrically at 280nm using an extinction coefficient relevant to the product.
Figure 2 shows the analysis of serum from sheep immunised with a toxoid of Toxin A. - Antibodies will be blended to form the final product such that the required neutralising activities against Toxins A and B and their various isoforms (toxinotypes) are present in the final mixture.
- Antibodies prepared against the various C. difficile toxinotypes may be blended in order to provide similar cross-protective efficacy as assessed in Example 10. For example, to provide similar cross-protection against C. difficile Toxin B derived from
Toxinotypes 0 and III, antibodies may be mixed in a various proportions (e.g. 1:1, 2:1, 1:2 ratios) in order to provide similar specific neutralising activity against each of the Toxin B toxinotypes. - To demonstrate the prophylactic (preventative) efficacy of antibodies against CDI in vivo, Syrian hamsters are passively immunised with ovine antibodies which have neutralising activity against one or more of the toxins of C. difficile. For assessing the prophylactic efficacy, hamsters will be given antibody either intravenously or by the intraperitoneal route at various times from 96 hours pre-challenge to 240 hours post challenge with C. difficile
- Passively immunised hamsters are administered with a broad spectrum antibiotic (e.g. clindamycin) and 12-72 h later challenged with C. difficile spores by mouth. Animals are then monitored for up to 15 days for symptoms of C. difficile-associated disease. Control, non-immunised animals develop signs of the disease (e.g. diarrhoea, swollen abdomen, lethargy, ruffled fur) while those passively immunised with ovine antibody appear normal.
- To demonstrate the efficacy of antiserum to treat CDI in vivo, Syrian hamsters are passively immunised with ovine antibodies which have neutralising activity against one or more of the toxins of C. difficile. For assessing the efficacy of a treatment formulation, hamsters will be given antibody either intravenously or by the intraperitoneal route at various times from 6 hours post-challenge to 240 hours post challenge with C. difficile
- Prior to passively immunisation hamsters are administered with a broad spectrum antibiotic (e.g. clindamycin) and 12-72 h later challenged with C. difficile spores by mouth. Animals are then monitored for up to 15 days for symptoms of C. difficile-associated disease. Control, non-immunised animals develop signs of the disease (e.g. diarrhoea, swollen abdomen, lethargy, ruffled fur) while those treated with ovine antibody appear normal.
- Three examples serve to illustrate the therapeutic value of the systemic ovine products in patients with differing degrees of seventy in their CDI.
- A 67 year old male was admitted to a coronary care unit following a severe myocardial infarction. He was making an uneventful recovery when he developed a mild diarrhoea without any other signs or symptoms. Because there had been recent episodes of CDI in the hospital, a faecal sample was sent immediately for testing and found to contain both Toxin A and Toxin B. After isolation to a single room with its own toilet he received 250mg of the ovine F(ab')2 intravenously followed by a second injection two days later. His diarrhoea stopped quickly and he made a full recovery without the need of either metranidazole or vancomycin.
- A female aged 81 fell in her home and sustained a fractured left hip. She was immediately admitted to hospital and the hip was pinned successfully. Her frail condition prevented early discharge and, a few days later, she developed a productive cough for which she was given a wide spectrum antibiotic. After a further eight days she developed profuse diarrhoea with abdominal pain and tenderness and CDI was diagnosed by the appropriate faecal tests. At the time there was also evidence of systemic manifestations of the infection including a markedly raised white blood cell count, and of significant fluid loss with dehydration. The patient was started immediately on oral vancomycin and, at the same time, received the first of five daily injections of 250mg of the ovine F(ab')2 - based product intravenously. There was a rapid resolution of the signs and symptoms and of the laboratory manifestations of CDI. However, in order to avoid the risk of relapse of her CDI following stopping vancomycin, she continued to be treated for a further two weeks on an oral form of the antibody therapy. She experienced no relapse.
- An 87 year old female developed bronchopneumonia while resident in long-stay care facilities. The local general practitioner started her on a course of antibiotic therapy with immediate benefit. However, eight days after stopping the antibiotic she experienced severe diarrhoea. Her condition started to deteriorate necessitating admission to hospital where Toxin A was detected in her faeces by an ELISA test. By this time she was extremely ill with evidence of circulatory failure and her diarrhoea had stopped. The latter was found to be due a combination of paralytic ileus and toxic megacolon and an emergency total colectomy was considered essential. Since such surgery is associated with a mortality in excess of 60% she received intravenous replacement therapy together with the contents of two ampoules (500mg) of product. By the time she was taken to the operating theatre four hours later, her general condition had improved significantly and she survived surgery.
- Syrian hamsters (groups of 10) were passively immunised (i.p.) with either ovine antibodies to Toxin A and B at 10 mg/dose (▼), 2 mg/dose (■) or with a non-specific control antibody (●) at the times indicated. Animals received clindamycin at Day -2 and at
Day 0 were challenged with C. difficile spores (2 x102 colony forming units). Survival, days post challenge are shown by the plots. - The data (see
Figure 3 ) clearly show that passive immunisation with a mixture of ovine antibodies to Toxins A and B affords protection from CDI. In this experiment, 90% of animal given the high antibody dose were asymptomatic at 12 days post challenge. - Syrian hamsters (groups of 10) were passively immunised (i.p.) with either ovine antibodies to Toxin A + B at 10 mg/dose (▼), Toxin A antibodies alone at 10 mg/dose (Δ), Toxin B antibodies alone at 10 mg/dose (○) or with a non-specific control antibody (□) at the times indicated. Animals received clindamycin at Day -2 and at
Day 0 were challenged with C. difficile spores (2 x102 colony forming units). Survival, days post challenge are shown by the plots. - The data (see
Figure 4 ) show that with respect to protection against CDI, the efficacy of a mixture of Toxin A + B antibodies is significantly better than either antibody given alone. - Syrian hamsters (groups of 10) were passively immunised (i.p.) with either ovine antibodies to Toxin A and B at 10 mg/dose (▼) or with a non-specific control antibody (■) at the times indicated. Animals received clindamycin at Day -3 and at
Day 0 were challenged with C. difficile spores (1 x103 colony forming units). Disease states at days post challenge are shown by the plots. - The data (see
Figure 5 ) clearly show that passive immunisation with a mixture of ovine antibodies to Toxins A and B affords protection from CDI induced by the 027, 'hypervirulent C. difficile (strain R20291, stoke Mandeville). In this experiment, 90% of animal given Toxin A/B antibody were asymptomatic at 18 days post challenge while 80% of the non-immunised controls showed severe symptoms of CDI. - Syrian hamsters (groups of 10) were passively immunised (i.p.) with either ovine antibodies to Toxin A and B at 10 mg/dose (▼) or with a non-specific control antibody (●) at the times indicated. Animals received clindamycin at Day -2 and at
Day 0 were challenged with C. difficile spores (2 x103 colony forming units). Disease states at days post challenge are shown by the plots. - The data (see
Figure 6 ) clearly show that passive immunisation with a mixture of ovine antibodies to Toxins A and B affords protection from CDI induced by the 078, 'hypervirulent C. difficile. In this experiment, 100% of animal given Toxin A/B antibody were asymptomatic at 18 days post challenge while 80% of the non-immunised controls showed severe symptoms of CDI. -
- 1. Clostridium difficile Toxin A -
Toxinotype 0 - 2. Protein Sequence of C. difficile Toxin B -
Toxinotype 0 - 3. Protein Sequence of C. difficile Toxin A - Toxinotype III
- 4. Protein Sequence of C. difficile Toxin B - Toxinotype III
- 5. Protein Sequence of C. difficile Binary toxin fragment A
- 6. Protein Sequence of C. difficile Binary toxin fragment B
Claims (7)
- An antibody composition comprising ovine polyclonal antibodies that bind to and neutralise the biological activity of C. difficile Toxin A and C. difficile Toxin B, for use in the prevention or treatment of C. difficile infection.
- The antibody composition for use according to claim 1, wherein:(a) the ovine polyclonal antibodies that bind to and neutralise the biological activity of C. difficile Toxin A are produced by immunisation of a sheep with an immunogen comprising at least 1500 amino acids of C. difficile Toxin A and having common antigenic cross-reactivity with the full length C. difficile Toxin A from which it was derived; and(b) the ovine polyclonal antibodies that bind to and neutralise the biological activity of C. difficile Toxin B are produced by immunisation of a sheep with an immunogen comprising at least 1500 amino acids of C. difficile Toxin B and having common antigenic cross-reactivity with the full length C. difficile Toxin B from which it was derived.
- The antibody composition for use according to Claim 1 or Claim 2, wherein the C. difficile toxin is a Toxin A selected from the following group: Toxinotype 0, Toxinotype III and Toxinotype V.
- The antibody composition for use according to any of Claims 1 to 3, wherein the C. difficile toxin is a Toxin B selected from the following group: Toxinotype 0, Toxinotype III and Toxinotype V.
- A pharmaceutical composition comprising ovine antibodies for use according to any one of claims 1 to 4, together with at least one component selected from a pharmaceutically acceptable carrier, excipient, and/ or salt for parenteral administration.
- A method of producing ovine antibodies for use according to any one of Claims 1 to 5, wherein the ovine polyclonal antibodies that bind to and neutralise the biological activity of C. difficile Toxin A are elicited in response to an immunogen comprising at least 1500 amino acids of C. difficile Toxin A and having common antigenic cross-reactivity with the full length C. difficile Toxin A from which it was derived and wherein the ovine polyclonal antibodies that bind to and neutralise the biological activity of C. difficile Toxin B are elicited in response to a C. difficile Toxin B immunogen comprising at least 1500 amino acids of a C. difficile Toxin B and having common antigenic cross-reactivity with the full length C. difficile Toxin B from which it was derived.
- The antibody composition for use according to claim 2 or the method according to Claim 6, wherein the immunogen is a C. difficile toxoid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0902851A GB0902851D0 (en) | 2009-02-20 | 2009-02-20 | Antibodies to clostridium difficile toxins |
GB0916153A GB0916153D0 (en) | 2009-09-15 | 2009-09-15 | Antibodies to clostridium difficile toxins |
PCT/GB2010/050288 WO2010094970A1 (en) | 2009-02-20 | 2010-02-19 | Antibodies to clostridium difficile toxins |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2405940A1 EP2405940A1 (en) | 2012-01-18 |
EP2405940B1 true EP2405940B1 (en) | 2021-08-04 |
Family
ID=42109880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10706731.6A Active EP2405940B1 (en) | 2009-02-20 | 2010-02-19 | Antibodies to clostridium difficile toxins |
Country Status (7)
Country | Link |
---|---|
US (2) | US8709428B2 (en) |
EP (1) | EP2405940B1 (en) |
JP (1) | JP5740714B2 (en) |
CN (1) | CN102365097A (en) |
AU (1) | AU2010215275B2 (en) |
CA (1) | CA2752815A1 (en) |
WO (1) | WO2010094970A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
US8431361B2 (en) * | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
SG10201602668VA (en) * | 2011-04-22 | 2016-05-30 | Wyeth Llc | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
GB201110712D0 (en) | 2011-06-23 | 2011-08-10 | Univ Ulster | Diagnostic methods |
MX2014002769A (en) * | 2011-09-16 | 2014-06-11 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile. |
EP2780351B1 (en) | 2011-11-18 | 2019-12-18 | National Research Council of Canada (NRC) | Clostridium difficile lipoteichoic acid and uses thereof |
JP6084631B2 (en) | 2011-12-08 | 2017-02-22 | ノバルティス アーゲー | Clostridium difficile toxin-based vaccine |
DE102011121237A1 (en) * | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Single domain antibody to Clostridium difficile toxin CDTa |
AR089797A1 (en) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | VACCINES AGAINST CLOSTRIDUM DIFFICILE THAT INCLUDE RECOMBINANT TOXINS |
CN104203976A (en) | 2012-03-02 | 2014-12-10 | 瑞泽恩制药公司 | Human antibodies to clostridium difficile toxins |
US20150259402A1 (en) | 2012-10-19 | 2015-09-17 | Evec Inc. | Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof |
BR122016023101B1 (en) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile |
CN109776676A (en) * | 2012-11-28 | 2019-05-21 | Cnj控股公司 | For the antibody of clostridium difficile |
US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
NZ713233A (en) * | 2013-04-19 | 2020-10-30 | Immuron Ltd | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease |
AU2014257172B2 (en) | 2013-04-22 | 2019-01-31 | Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
CN103665141B (en) * | 2013-12-31 | 2015-09-16 | 北京大学 | Albumen interactional with G. difficile cytotoxin B |
EP3126840B1 (en) * | 2014-04-01 | 2020-05-06 | Institut Pasteur | Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome |
WO2017040885A1 (en) | 2015-09-03 | 2017-03-09 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
USD952157S1 (en) | 2020-06-19 | 2022-05-17 | Qualigen Inc. | Whole blood treatment cartridge |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS608225A (en) | 1983-06-29 | 1985-01-17 | Kowa Co | Drug composition for alimentary canal absorption |
US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
NZ291659A (en) | 1994-09-06 | 2001-04-27 | Galagen Inc | Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile |
US6096310A (en) | 1997-04-15 | 2000-08-01 | Bier; Milan | Oral immunotherapy of bacterial overgrowth |
AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
DE69829400T2 (en) | 1997-10-20 | 2006-04-13 | Acambis, Inc., Cambridge | PASSIVE IMMUNIZATION AGAINST CLOSTRIDIUM DIFFICILE DISEASE |
US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
US6074689A (en) | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
US20020009429A1 (en) | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
GB0205206D0 (en) | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
AU2003299527A1 (en) | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
PL2857418T3 (en) * | 2004-02-06 | 2017-10-31 | Univ Massachusetts | Antibodies against Clostridium difficile toxins and uses thereof |
CA2592015A1 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
US7794721B2 (en) | 2006-12-13 | 2010-09-14 | Simon Michael R | Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith |
CN101363867B (en) | 2008-05-26 | 2012-12-19 | 北京庄笛浩禾生物医学科技有限公司 | Test paper strip for detecting clostridium difficile toxin A and toxin B colloidal gold, method for making same |
GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
-
2010
- 2010-02-19 CA CA2752815A patent/CA2752815A1/en not_active Abandoned
- 2010-02-19 AU AU2010215275A patent/AU2010215275B2/en active Active
- 2010-02-19 CN CN2010800086731A patent/CN102365097A/en active Pending
- 2010-02-19 US US13/202,557 patent/US8709428B2/en active Active
- 2010-02-19 JP JP2011550652A patent/JP5740714B2/en active Active
- 2010-02-19 EP EP10706731.6A patent/EP2405940B1/en active Active
- 2010-02-19 WO PCT/GB2010/050288 patent/WO2010094970A1/en active Application Filing
-
2014
- 2014-03-18 US US14/218,854 patent/US20150010580A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
A. ROBERTS ET AL: "DEVELOPMENT AND EVALUATION OF AN OVINE ANTIBODY-BASED PLATFORM FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION", INFECTION AND IMMUNITY, vol. 80, no. 2, 1 February 2012 (2012-02-01), pages 875 - 882, XP055059618, ISSN: 0019-9567, DOI: 10.1128/IAI.05684-11 * |
ANTHONY F. PIZON ET AL: "Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations", ACADEMIC EMERGENCY MEDICINE, vol. 14, no. 4, 1 April 2007 (2007-04-01), US, pages 373 - 376, XP055343366, ISSN: 1069-6563, DOI: 10.1197/j.aem.2006.10.095 * |
RICHARD C. DART ET AL: "Efficacy, safety, and use of snake antivenoms in the United States", ANNALS OF EMERGENCY MEDICINE, vol. 37, no. 2, 1 February 2001 (2001-02-01), pages 181 - 188, XP055165220, ISSN: 0196-0644, DOI: 10.1067/mem.2001.113372 * |
TAMMI H SCHAEFFER ET AL: "Treatment of Chronically Digoxin-Poisoned Patients With a Newer Digoxin Immune Fab-A Retrospective Study", J AM OSTEOPATH ASSOC, vol. 110, no. 10, 1 October 2010 (2010-10-01), pages 587 - 592, XP055343373 * |
Also Published As
Publication number | Publication date |
---|---|
US20120121607A1 (en) | 2012-05-17 |
CN102365097A (en) | 2012-02-29 |
US20150010580A1 (en) | 2015-01-08 |
CA2752815A1 (en) | 2010-08-26 |
JP5740714B2 (en) | 2015-06-24 |
US8709428B2 (en) | 2014-04-29 |
EP2405940A1 (en) | 2012-01-18 |
WO2010094970A1 (en) | 2010-08-26 |
AU2010215275B2 (en) | 2016-03-31 |
JP2012518624A (en) | 2012-08-16 |
AU2010215275A1 (en) | 2011-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2405940B1 (en) | Antibodies to clostridium difficile toxins | |
US20210369830A1 (en) | Clostridium difficile antigens | |
EP1708743B1 (en) | Passive immunization against clostridium difficile disease | |
US7442373B2 (en) | Antibodies against protective antigen and methods of use for passive immunization and treatment of anthrax | |
CA2307331C (en) | Passive immunization against clostridium difficile disease | |
EP0648127B1 (en) | Type i surface antigens associated with staphylococcus epidermidis | |
EP2844283B1 (en) | Clostridium difficile antigens | |
US5955293A (en) | Assays for shiga toxin and shiga-like toxins | |
Hiriart et al. | Preclinical studies of NEAST (neutralizing equine anti-Shiga toxin): a potential treatment for prevention of Stec-Hus | |
EP2570433A1 (en) | Neutralizing human antibodies to anthrax toxin generated by recall technology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110919 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1160379 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MICROPHARM LIMITED Owner name: THE SECRETARY OF STATE FOR HEALTH |
|
17Q | First examination report despatched |
Effective date: 20150205 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MICROPHARM LIMITED Owner name: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602010067367 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0039400000 Ipc: C07K0016120000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/04 20060101ALI20210121BHEP Ipc: C07K 16/12 20060101AFI20210121BHEP Ipc: A61K 39/00 20060101ALI20210121BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE Owner name: MICROPHARM LIMITED |
|
INTG | Intention to grant announced |
Effective date: 20210310 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE Owner name: MICROPHARM LIMITED |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SHONE, CLIFFORD Inventor name: LANDON, JOHN |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1416914 Country of ref document: AT Kind code of ref document: T Effective date: 20210815 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010067367 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1160379 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1416914 Country of ref document: AT Kind code of ref document: T Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211104 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211104 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211206 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010067367 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20220506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220228 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230526 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100219 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240223 Year of fee payment: 15 Ref country code: NL Payment date: 20240215 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240225 Year of fee payment: 15 Ref country code: GB Payment date: 20240223 Year of fee payment: 15 Ref country code: CH Payment date: 20240301 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240223 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210804 |